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Abstract
Periconceptional Treatment with Growth Hormone Alters Fetal Growth and
Development in Sheep

Jill Marie Koch

Altering the fetal environment can modify the composition or growth rate of
the fetus, a concept known as fetal programming. A majority of the research in
this area has focused on intrauterine growth restriction (IUGR), which has been
linked to adult diseases. A few studies have attempted to ameliorate the
negative effects of IUGR, by applying growth promoters late in gestation, and
have only observed transient effects. Our laboratory has previously shown that
growth hormone (GH) treatment around the time of breeding alters the uterine
environment early in gestation and results in larger lambs at birth. Therefore
there were three main objectives investigated in the current work, each
encompassing a different period of gestation. The first objective was to examine
how a periconceptional injection of GH alters the uterine environment at the time
of early embryonic development and if the trophectoderm to inner cell mass ratio
is altered by treatment. The second objective was to determine how GH
treatment may program nutrient transport in the placenta late in gestation. The
third objective was to examine how a periconceptional injection of GH alters fetal
growth and development at birth and how the GH axis may be altered in lambs
born to ewes treated with GH. Periconceptional GH treatment altered the
concentration of growth factors in uterine luminal fluid including TGF-ß1, insulin
like growth factor-I and urea, but did not alter the ratio of trophectoderm to inner
cell mass cells or the total number of blastomeres. Treatment with GH appeared
to alter the placental expression of some nutrient transporters during gestation.
Periconceptional treatment with growth hormone appears to alter the uterine
environment during embryonic development, programming the cells of the
embryo to exhibit an altered physiology. Periconceptional GH treatment
increased lamb weight and abdominal girth. Lambs born to ewes treated with
GH also had an altered GH axis as determined by a reduced hepatic expression
of both insulin like growth factor-I and growth hormone receptor at birth and an
altered response to GH releasing hormone challenge at 100 days of age.
Periconceptional GH appears to program embryonic cells which develop into a
more efficient placenta allowing for an increase in nutrient availability, ultimately
leading to larger lambs at birth with an altered composition and an altered growth
hormone axis.
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Literature Review
Fetal Programming
Fetal programming is described as any environmental insult or stimulus
that occurs during the development of key organs or tissues and results in long
lasting or permanent physiological alterations of the offspring (Godfrey and
Barker, 2000; Armitage et al., 2004). The amount of data collected on fetal
programming is vast and includes both retrospective studies in humans and
prospective studies in animals. The concept of fetal programming stems from
the “Barker Hypothesis” which developed from the medical records of adults who
were gestated during the Dutch famine. During this period, daily caloric intake
dropped as low as 580 calories (Ravelli et al., 1976). The epidemiological data
collected from these humans gestated during the Dutch famine linked low birth
weight with several adult onset diseases. More specifically, low caloric intake
during early gestation was linked to hypertension, but limited caloric intake during
late gestation has been linked to adult obesity and glucose intolerance (i.e.,
metabolic disorders; Barker, 1995; Ravelli et al., 1999; Ameritage et al., 2004).
Exposure to an insult or a stimulus that result in long lasting and
permanent physiological alterations is a phenomenon known as programming
(Godfrey & Barker, 2000). The impact of the uterine environment on fetal growth
and development is more specifically known as fetal programming. The “fetal
origins” hypothesis suggests fetal programming results in permanent alterations
in the structure, physiology and metabolism of the offspring, which predisposes
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them to adult onset diseases (Barker 1995; Godfrey & Barker 2000). In fact, the
use of animal models has allowed researchers to link a deleterious uterine
environment during specific stages of fetal development to altered development
and function (i.e., program) of the cardiovascular, respiratory, endocrine,
reproductive, skeletal, immune and central nervous systems as well as the
function of the kidneys and liver (Godfrey and Barker, 2000; Wu et al., 2004).
The influence of the uterine environment from ovulation through birth
permanently impacts the development of the offspring, ultimately influencing the
health of the adult. It has been suggested that the offspring’s genotype
contributes only 15% to the variation in birth weight, while maternal environment
(i.e., nutrition available to the fetus) has double the influence at 30%. The
remaining 55% is influenced by other stimuli (i.e., maternal size and uterine
environment; Nathanielsz, 2000). Animal models can be utilized to assess the
impact of an altered uterine environment both in vivo and ex vivo. The use of
animals allows critical assessment of the effect of uterine environment (i.e.
secretion, timing and space) on embryonic development, fetal growth and
ultimately postnatal life.

Embryonic and Early Fetal Development
Embryonic Development
In sheep, the oviduct is the sight of fertilization and as such it is
responsible for providing the proper environmental conditions in which early
embryonic development occurs. For fertilization to occur, the gametes must first
2

be transported to the site of fertilization at the ampullary-isthmic junction. Sperm
travel from the site of deposition in the most exterior portion of the cervix to the
ampullary-isthmic junction. The cilia in the upper portion of the oviduct always
beat toward the site of fertilization (toward the uterus) and move oocyte to the
ampullary-isthmic junction. However, the other parts of female reproductive tract
are sensitive to the estrogen to progesterone ratio. A high estrogen to
progesterone ratio results in contraction of the female reproductive tract toward
the site of fertilization while a low ratio stimulates oviductal contractions which
move the zygote (i.e., fertilized oocyte) toward the uterus (Crisman et al., 1980).
The fertilized ovum starts as a single cell surrounded by a glycoprotein
layer called the zona pelucida (Figure 1). The first divisions of the embryo are
synchronous and called cleavage divisions. Cleavage divisions take place until
the embryo becomes a morula. In the sheep, the embryo enters the uterus in the
morula stage on day four following mating (Figure 1; Spencer and Bazer, 2004;
Spencer et al., 2004). The cells of the morula will become one of two embryonic
cell types in the blastocyst, either the inner cell mass or the trophectoderm. The
trophectoderm is a single layer of cells connected by gap junctions. These cells
form a barrier around the inner cell mass and allow for the formation of a fluid
filled cavity called the blastocoele. The trophectoderm develops into the chorion
portion of the placenta. The inner cell mass is a ball of cells located inside the
trophectoderm. The inner cell mass will develop later into the embryo proper and
eventually the fetus and portions of the placenta. Transition from a morula to a
blastocyst takes place in the uterus and only requires about 48 hours (day six of
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pregnancy). The morula transforms into a compact morula with trophectoderm
cells forming on the outside and inner cell mass cells on the inside. As the
blastocyst continues to develop a blastocoelic cavity forms. Further development
between days six and eight leads to the blastocyst hatching out of the zona
pelucida (Spencer et al., 2004). It is not until around day eleven that the embryo
starts to elongate going from a round sphere to a more filamentous shape.
Growth continues to increase dramatically as the size of the embryo goes from
about 30 mm on day 12 to about 190 mm by day 16 (Spencer et al., 2004).
Around day 12, the embryo starts to produce vast quantities of interferon τ.
Interferon τ is considered to be one of the molecules secreted by the embryo that
signals maternal recognition of pregnancy and is thought to be stimulated by
proper histotrophic nutrition (Gray et al., 2000; Gray et al., 2002; Spenser and
Bazer, 2004). Prior to day 16, the trophectoderm of the embryo has only been
loosely associated with the endometrium; however, around day 16 the embryo
starts to adhere to the endometrium (Spencer and Bazer, 2004; Spencer et al.,
2004). The lack of any permanent attachments until day 16 limits the nutrients
available to the embryo to just those found in the lumen of the oviduct and the
uterus (i.e., histotrophic nutrition).
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FIGURE 1. Schematic demonstrating early embryonic cell division and growth
from fertilization up to day 16 of pregnancy as well as the progesterone and
estrogen profile during this period. Redrawn from Spencer et al., 2004.
Reproduction. 128:657-668.

Oviduct Environmental Influence
The oviductal fluid contains vitamins, amino acids, carbohydrates
(glucose, pyruvate and lactate) growth factors, enzymes and proteins (Gandolfi
et al., 1989; Nancarrow and Hill, 1995; Buhi et al., 2000; Killian, 2004; Aguilar
and Reyley, 2005). The components of the oviductal fluid are similar to plasma
with the exception of a few proteins secreted only by the oviduct. For example,
the concentration of some amino acids (methionine, leucine, phenylalanine,
lysine, aspartic acid, glycine, alanine, taurine, tyrosine) are actually only 25% of
that which is observed in plasma, while others (threonine, serine, ornithine) are
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actually higher in oviductal fluid (Aguilar and Reyley, 2005). Compared to other
species, only a small list of growth factors have been detected in sheep oviductal
fluid and include basic fibroblast growth factor, insulin-like growth factor binding
proteins 3 and 4, insulin Iike growth factor-I and II, transforming growth factor α
and ß and prostaglandins E2 and F2α (Aguilar and Reyley, 2005).
Oviductal fluid only contains one tenth the protein found in plasma and it
comes from two sources. The primary source is plasma which provides proteins
like albumin, immunoglobulins and high density lipoproteins which are present in
the oviduct at a constant concentration and make up approximately 95% of the
total protein found in oviductal fluid (Gandolfi et al., 1989; Killian, 2004; Aguilar
and Reyley, 2005). The secondary source of protein are those produced and
secreted by the epithelium that lines the oviduct. In sheep, and most other
mammals, a group of oviduct specific glycoproteins or “oviductins” are only
synthesized by oviductal epithelium. These glycoproteins contribute to the
extracellular matrix of the embryo, the oviduct micro environment and interact
with the zona pelucida (Gandolfi et al., 1989; Murray, 1993; Buhi et al., 2000).
Estrogen stimulates the oviductal epithelial cells to synthesize and secrete
oviductins such that they are high at estrus. Not surprising, these proteins are
secreted, coincident with the time in which an embryo would be present, from
day two to four and dropping to undetectable levels on day four shortly after the
embryo should enter the uterus (Sutton et al., 1986; Murray, 1993).
The importance of oviductal proteins is evident from a study on in vitro
embryo development in which approximately 90% of single cell embryos co6

cultured with oviduct somatic cells developed to at least the eight cell stage,
while only 13% of those cultured without cells reached the same developmental
stage (Gandolfi and Moor, 1987). The type of somatic cell used for co-culture
also impacted embryonic development. Embryos co-cultured with either
oviductal epithelium or fibroblasts did not appear to have altered growth from day
zero (fertilization) to day three, but when transferred back into recipient females
only 33% of those cultured with fibroblasts continued to develop compared to
80% development in those cultured with oviductal epithelium (Gandolfi and Moor,
1987). Others have demonstrated that including the glycoprotein fraction of
oviductal fluid decreases the number of in vitro fertilized embryos that go through
the first cleavage division, but including it in culture media increased the number
of cloned embryos which developed to the blastocyst stage, which may suggest
that it is more influential for older embryos (Nancarrow and Hill, 1995). These
experiments are consistent with a role for the oviductal milieu in proper
embryonic development and provide a physiological mechanism as to how
alterations to the pregnant female very early in pregnancy may permanently alter
the embryonic cells.
Uterine Environmental Influences
The uterine environment can exert its influences through either
histotrophic (oviductal and uterine fluid derived nutrients) or hematotrophic
(maternal blood derived) nutrition and a gestational stage specific milieu is
thought to be essential for normal conceptus growth and survival. Collectively,
these two nutrient sources play a major role in embryonic development,
7

attachment and placentation (Gray et al., 2001; Spencer and Bazer, 2004).
Histotrophic nutrients are synthesized and secreted by the glandular epithelium
of the uterus (i.e., uterine glands). Secretion of historophic nutrients is regulated
by maternal and embryonic hormones (progesterone, estrogen and interferon τ).
The second source of nutrients is hematotrophic, which describes the transfer of
nutrients from maternal blood into fetal blood and is altered mainly by changes in
uterine and umbilical blood flow (i.e., as uterine blood flow increases the amount
of hematotrophic nutrition increases; Gray et al., 2001; Spencer and Bazer,
2004). Histotrophic nutrients bathe the embryo in the uterus and consist of
enzymes, growth factors, ions, cytokines, hormones, adhesion molecules and
transport proteins (Spencer and Bazer, 2004; Igwebuike, 2006). Different
experimental models have been utilized to examine the effects of altered uterine
environment on embryonic growth and development and include embryo transfer,
advancing the uterine environment and blocking the histogenesis of uterine
glands.
It has been understood for a least 50 years that transferring embryos in
any species requires a relatively high degree of synchrony between the donor
and recipient. In the ewe, the embryo can tolerate uterine asynchrony up to a
two day window. This means that the synchrony of the recipient female and the
donor embryos must be within two days, but for optimal embryonic survival the
donor and recipient should be at the exact same day following estrus (Moore and
Shelton, 1964; Rowson and Moor, 1966; Wimut and Sales, 1981; Ashworth and
Bazer, 1989). Extending the window of transfer from 48 to 72 hours in either
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direction of the embryonic stage (an additional 24 hours in either direction)
decreases the success of embryo transfer by about 65% (~8% survive when
transferred at ± three days; Rowson and Moor, 1966). Not only does the window
of opportunity impact success rate, but the stage of embryonic development at
the time of transfer impacts overall success rate. A time-dependent increase
was observed in that, as the age of the embryo increased the rate of survival
increased independent of recipient synchronization within a 48 hour window
(Moore and Shelton, 1964). Similar results were found by Rowson and Moor
(1966) in which day five embryos (morulas) transferred to day seven recipients
had a lower survival rate than day nine embryos (blastocysts) transferred into a
day eleven recipient. Zygotes cultured for six days in control conditions, cocultured with granulosa cells, or cultured in synthetic oviductal fluid with or
without serum, before being transferred back to day 6 recipients, demonstrated
the effect of early environment on fetal growth and development. Fetuses
derived from granulosa cell co-culture were 14% heavier by day 61 of gestation
and 18% larger compared to controls on day 125. Those cultured with synthetic
oviductal fluid plus serum were18% heavier, compared to those cultured without
serum, by day 125. There was also an increase in the calculated growth
coefficient for the liver and heart for the co-culture and synthetic oviductal fluid
plus serum compared to control cultures (Sinclair et al., 1999). These results
demonstrate that uterine environment is critical to survival and altering the
uterine milieu can alter the natural growth curve and alter fetal development.
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Progesterone administration is one mechanism used to study the impact
of the uterine environment on embryonic development. Progesterone
administration during early pregnancy has been found to advance the uterine
environment and lead to altered embryonic growth. Fetal growth was increased
in ewes exposed to progesterone from days 1-3, 3-6 or 1-6 of gestation.
Progesterone treatment starting on day one had the greatest impact on fetal
growth in that both fetal mass and crown-rump length were increased (Kleeman
et al., 1994). Embryos transferred to a more advanced uterine environment were
found to be 42% heavier at day 21 of gestation (Young et al., 1996). When day
three embryos were transferred to a uterine environment advanced by three days
(i.e., day 6 environment), for three days, and then transferred back to a day six
environment, the fetuses that developed had alterations in muscle development.
While there was no difference in fetal weight or crown-rump length, those
embryos transferred to an asynchronous environment had a greater number of
muscle fibers compared to those maintained in a synchronous environment
(Maxfield et al., 1998). This indicates that only a small change in the embryonic
environment, for a short amount of time, can result in “fetal programming.”

Placental Anatomy
The placenta’s function is to provided a physiological exchange
mechanism between the fetus and dam removing waste from the fetus,
exchanging gas and providing nutrients for proper fetal growth. The sheep
placenta has two general regions 1) placentomal region and 2) interplacentomal
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regions (Igwebuike, 2006). The placentomes are areas in which cotyledonary
villi (fetal placenta) penetrate deep into the caruncular tissue (maternal
attachment points) creating areas for hematotrophic nutrition, as well as gas and
waste exchange (Figure 2; Reynolds et al., 2005a). These villi are lined with
microvilli that increase surface area for nutrient absorption. Placental growth is
exponential from establishment (approximately day 24) with the number of
possible placentomes between 60 and 100 per placenta being determined by day
56 of gestation (Renyonlds et al., 2005; Igwebuike, 2006). The placenta,
primarily cotyledonary tissue, will continue to proliferate until about day 80 going
from 15 g at day 40 to 770 g at day 80 of gestation when the mass of the
placenta dramatically declines (441g day 100), but angiogenesis increases
exponentially (Ehdart and Bell, 1995). Placental weight has been correlated with
fetal development late in gestation in that 80% of the variation in fetal weight can
be accounted for by variation in placental weight which may indicate that a poorly
developed placenta results in a poorly developed fetus (Bell et al., 1999).
As gestation progresses and fetal nutrient demand increases placentome
morphology changes to meet these needs. Placentomes are characterized into
four different groups (A, B, C and D type) based on cotyledonary tissue growth.
Type A are spherical placentomes in which the fetal cotyledonary tissue is
completely surrounded by maternal caruncular tissue and are concave in the
middle (cotyledonary tissues is sunken into the middle of caruncular tissue).
Type B placentomes can be described as those in which fetal tissue is starting to
grow over top of the maternal caruncular tissue. Type C placentomes are flat on
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top (cotyledonary tissue has completely filled the caruncle) and cotyledonary
tissue only completely covers one surface of the caruncle which means that the
sides of the caruncle are still visible. Type D placentomes are flat and everted.
Fetal cotyledonary tissue is completely covering the top and sides of the
maternal caruncular tissue (Osgerby, et al., 2004; Vonnahme et al., 2006)
Ruminants, including the sheep and cow, have the least intimate contact
between maternal and fetal circulation with six tissues layers between the
maternal and fetal circulations and this occurs in the area of the placentome
which makes up approximately 95% of the total interactive surface area
(Wooding et al., 2005). These layers consist of three layers on the maternal side
including endothelium, stroma and epithelium (syncytium) and three fetal layers
including epithelium (trophoblast cells), stroma and fetal endothelium (Figure 2;
Bjorkman, 1965). This type of placentation is called epitheliochorial because
there are two complete and intact layers of epithelium. It is important to note that
sheep can have only five layers, in this instance the maternal epithelium is
transiently eroded, which can regrow, but it leaves short periods of time when the
maternal epithelium is fused with fetal epithelium. As a result sheep are
sometimes known as having a syndesmochorial placenta (Reynolds et al.,
2005a).
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FIGURE 2. Schematic of the sheep placentome including caruncular and
cotyledonary tissue layers. The arrows indicate blood flow. (Redrawn from
Senger, PL. 1999. 2nd Edition Pathways to Pregnancy and Parturition). The
second portion of the schematic includes a close up of the six tissue layers in the
epithelialchorial placenta of the sheep.
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Placental Vasculature
In sheep, placental growth (in terms of weight) slows dramatically around
day 80 of gestation yet nutrient delivery and transport must keep up with
demands of the developing fetus. Under normal pregnancy conditions, umbilical
blood flow, oxygen transport and water transport all increase faster than fetal
weight as a way to compensate for growth of the fetus and lack of growth by the
placenta (i.e., extraction rate of nutrients increases; Reyonlds and Redmer,
1995). A more influential mechanism to keep up with the exponential growth of
the fetus is a three to four fold increase in uterine blood flow between mid to late
gestation, which results in an increase in the amount of nutrients available for
extraction (Rosenfeld et al., 1974).
Concurrent with the dramatic increase in blood flow is an increase in
angiogenesis of the placentome. The number of vascular changes in the
maternal caruncular tissue is relatively small compared to vascular growth of fetal
cotyledonary tissue, but both have an increase in angiogenesis (Table 1;
Reynolds et al., 2005a; Reynolds et al., 2005b). Capillary area density, capillary
number density and capillary surface area all increase between day 50 and 140
of gestation in both maternal and fetal tissue (Table 1; Reynolds et al., 2005a;
Reynolds et al, 2005b). The major difference between maternal and fetal
circulation in the placenta is the type of vessels found. Maternal vessels are
larger, with less surface area and are indicative of vessels that have slower
velocity to increase time for extraction by the placenta. Fetal cotyledonary
vessels on the other hand are smaller, with small branching architecture, which is
14

best utilized in systems with high velocity to allow for quick nutrient absorption
(Reynolds and Redmer, 1995; Reynolds et al., 2005a). These alterations in
blood flow and the capillary networks compensate for the limited growth of the
placenta in the second half of gestation by increasing the extraction efficiency of
the placenta. Increasing placental efficiency by vascular adaptations is further
demonstrated by using carunclectomized sheep. In this model a portion of
caruncles are removed from the uterus of the ewe limiting the number of
placentomes that can be formed. Late in gestation, uterine and fetal blood flow
and placental size are decreased when compared to intact controls, leading to
restricted fetal growth. It is speculated that the limited transport of nutrients
results from a reduction in the capillary surface area (as a result of reduced
placentome number) required for nutrient exchange (Robinson et al., 1995). In
some circumstances the limited number of placentomes that do exist undergo
extensive proliferation and are able to provide a greater area for nutrient
exchange than observed in placentomes of intact controls allowing for normal
fetal growth (Robinson et al., 1995).
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Capillary
Capillary No.
Area Density Density

Capillary
Surface
Density

Area per
Capillary

Fetal
6.2x
(Cotyledonary)

12.3x

6.0x

(-)1.9x

Maternal
(Caruncular)

1.5x

1.7x

2.2x

3.3x

TABLE 1. Maternal (caruncular) and fetal (cotyledonary) angiogenic changes that
occur between day 50 and 140 of gestation. All measures increase except for
area per capillary in cotyledonary tissue (Reynolds et al., 2005a).

Nutrient Transporters
Nutrients have to be in sufficient supply and delivered to the developing
fetus in a timely fashion for proper growth and development. In the last third of
gestation, a period in which fetal growth increases exponentially, limiting fetal
nutrient availability has been directly linked to intrauterine growth restriction and
long term alterations in organ function. The mechanisms by which this occurs
includes a decrease in maternally derived nutrients or insufficient transport of
nutrients across the placenta (Barker 1995; Ravelli et al. 1999; Godfrey & Barker
2000; Jensen et al. 2002; Armitage et al. 2004; Wu et al. 2004; Wallace et al.
2005; Wu et al. 2006). Until recently, investigators have suggested that limiting
nutrient availability was the cause of fetal growth restriction; however, recently
some have argued that if the number of transporters are limited, no matter what
the nutrient availability intrauterine growth restriction occurs (Jansson et al.,
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2006). There are several mechanisms utilized to transport nutrients across the
placenta and include facilitated diffusion, passive transport down a concentration
gradient, and endocytosis.
Glucose Transporters
Glucose is essential to the fetus because it is the primary substrate for
fetal energy metabolism and is obtained from maternal circulation via placental
transport (Robertson and Karp, 1976; Jansson et al., 1993; Bell et al. 1999).
Under normal gestational conditions, in which the dam is well-nourished, glucose
accounts for approximately 60% of the net uptake of carbon to the gravid uterine
horn and transport increases five to eight fold in the last third of gestation
(Jansson et al. 1993; Carver and Hay 1995; Chung et al. 1998; Bell et al. 1999;
Dandrea et al. 2001). Glucose appears to be passively transferred to the fetus
by a concentration-dependent mechanism as the transporters identified are all
sodium independent (Limesand et al., 2004; Wooding et al., 2005). Because
glucose is passively transferred to the fetus, maternal glucose concentration has
to remain higher than fetal glucose concentrations (Hay, 1995). This
concentration gradient is maintained by two mechanisms. The first is an
increasing rate of consumption by the growing fetus and placenta clearing fetal
blood of glucose and the second is maternal development of glucose tolerance
and insulin resistance raising blood glucose concentrations in maternal blood.
Glucose transporter 1 (GLUT-1) glucose transporter-3 (GLUT-3; both are
sodium independent) and glucose transporter 8 (GLUT-8; sodium dependent) are
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the only glucose transporters that have been identified in the sheep placenta.
Total placental mRNA expression and protein abundance of GLUT-1 and GLUT3 increase with an increase in the demand for glucose by the fetus. The greatest
expression and abundance for GLUT-1 varies with the number of fetuses and the
technique used to analyze mRNA. Currie and coworkers (1997) utilized PCR
and reported that GLUT-1 expression peaked at day 60 of gestation, whilel
Ehrhardt and Bell (1997) used northern blotting and reported an increase in
GLUT-1 expression increases from day 75 to 140 in twin pregnancies (Ehrhardt
and Bell, 1997). However, both expression and protein abundance for GLUT-3
increased from day 60 till term. Approximately 86% of all glucose binding sites
on day 75 are predicted to be GLUT-1 but by day 140 this drops to only 56%
(Ehrhardt and Bell, 1997). Glucose transporter-3 and not GLUT-1 transports the
majority of glucose required by the fetus at the end of gestation. The shift to
primarily GLUT-3 transport may be a result of a decrease in glucose binding to
GLUT-1 as well as a reduction in both mRNA and protein. Glucose transporter 8
also increased as gestation progressed (Limesand et al., 2004). The increased
capacity of the placenta to transport glucose appears to be a function of three
things. First is an increase in the total amount of transporter. Second, the
increase in capillary density and thereby total surface area leading to a much
greater increase in the total number of glucose transporters beyond a simple
increase in relative expression. Third the increase in the concentration gradient
that occurs in the last third of gestation (Molina et al., 1991; Hay, 1995).
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Glucose transporter-1 has been found on the basal and apical surface of
the fetal epithelium (trophoblast; Das et al., 2000; Wooding et al., 2005). The
localization of GLUT-3 has been detected on the apical surface of the
trophectoderm (Das et al., 2000; Wooding et al., 2005). Glucose transporter-8
has only been localized to the chorionic epithelium without a specific membrane
border given (Limesand et al., 2004). It has been speculated that because of the
differential localization of these isoforms, glucose must utilize different isoforms
sequentially to be able to pass from maternal circulation to fetal circulation in
sheep to meet the glucose demands of the growing fetus.
Amino Acid Transporters
Amino acids are the building blocks of all proteins, including those proteins
synthesized in utero by the developing fetus and placenta. The essential amino
acids are not synthesized, but extracted from maternal circulation and
transported to fetal circulation, via placental amino acid transporters (Cetin, 2001;
Kudo and Boyd, 2002). Therefore, alterations in placental amino acid transporter
number or transporter function may lead to intrauterine growth restricted fetuses.
On the opposite side an increase in the functionality of these transporters may
allow for an increase in the amino acid concentration in fetal circulation leading to
an increase in fetal growth and development.
Amino acid transporters have been classified into many different
categories based on ion-dependence, substrate specificity, kinetics, the type of
amino acid transported (i.e., neutral, anionic, cationic, branched chain or
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aromatic) and possible interactions with an additional subunit (Table 2; Jansson,
2001; Kudo and Boyd, 2002; Regnault et al., 2005). Amino acid transporters do
not specifically transport just one amino acid, but transport amino acids with
similar structural characteristics (Kudo and Boyd, 2002). This also means that
net amino acid transport in any direction (maternal to fetal or fetal to maternal)
may require the use of more than one amino acid transport system. Amino acid
transporters are located in all cell types throughout the body, but not all of these
amino acid transporters have been identified in the placenta and the majority of
information known about location of amino acid transporters in placental tissue is
limited mainly to human and rodent species. The human has a hemochorial
placenta in which maternal blood bathes the fetal trophoblast while the rodent
has a hemoendothelial in which maternal blood bathes the fetal endothelium.
The trophoblast in this instance is the barrier for amino acid transport, but in the
sheep, amino acids would have to cross both maternal and fetal epithelia and
endothelia before entering fetal circulation. The table provided below
summarizes the type of transporters known in human placenta and includes the
system type, the gene, substrates moved by the transporter membrane, location
in human fetal trophoblast cells and the type of transporter.
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TABLE 2. Amino acid transporter systems, gene name, amino acids transported,
the location of transported in fetal trophoblast cells in the human and the type of
transport system.

Placental Efficiency
Placental efficiency is defined as the grams of fetus that can be supported
by each gram of placenta and is calculated simply as fetal weight divided by its
placental weight. The size of the placenta and more specifically the surface area
available for nutrient exchange impacts placental efficiency. When placental
weight is used as a crude measure for total placental contact (meaning the larger
the placenta the greater likelihood for surface area contacts) it is positively
correlated to body weight (Fowden et al., 2006). However, the efficiency of the
placenta is more important and it is those placentas that fall above he trend line
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reflects placenta that are the most efficient meaning they produce the greater
amount of fetal weight with a smaller placental weight. In sheep average birth
weight of twins and triplets is approximately 80% (4.4 kg) and 70% (3.6 kg) of a
singleton lambs (5.4 kg). The number of placentomes is reduced by
approximately 40% per twin and approximately 75% per triplet compared to a
singleton fetus (total placentome mass 0.7 kg), but the placenta is able to change
and compensate for the lack of nutrient exchange areas (Gootwine et al., 2007).
Placental efficiency and the ability of the placenta to compensate has also been
examined under experimental conditions, including uterine ligation and nutrient
restriction.
Uterine ligation limits pregnancy to only one uterine horn limiting the
number of caruncles available to form placentomes (Bazer et al., 1979; Caton et
al., 1984; Ott et al., 1997). Uterine ligation results in a reduction in placentome
number between 23% and 50%. In experiments when the total number of
placentomes was reduced 50%, by day 140 of gestation fetal weight, placental
weight and cotyledonary weight were reduced (Caton et al., 1984). However, in
experiments in which only a 23% reduction in placentome number was observed
in uterine ligated animals, there was no difference in fetal size (crown-rump
length or weight), total placentome weight or placentome weight to fetal weight
ratios. In fact, individual placentome weight increased by 27% in ligated animals
which was mainly a result of an increase in the cotyledonary portion (Ott et al.,
1997).
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Limiting maternal nutrition limits nutrients available to the fetus. In
extreme conditions, such as a 50% reduction in nutrient intake, the placenta
compensates by increasing placentome size (specifically the cotyledonary
portion) and therefore increasing the surface area available for exchange. These
experiments further demonstrate that the placenta has the ability to become
more efficient when fetal nutrient demand increases. When pregnant ewes were
restricted to 50% of control diet, the type of placentomes that developed
indicated that an increase in angiogenesis had occurred, as a means of
attempting to compensate for nutrient restriction. On day 78 of gestation, after
50 days of restriction, the majority of placentomes in control ewes were of the A
type, while the nutrient restricted group had a larger proportion of the B, C and D
type placentomes (Vonnahme et al., 2006). In this experiment, placental
efficiency was not different between nutrient restricted and control ewes. The
placentas ability to compensate for poor nutrition is further demonstrated utilizing
the undernourished adolescent ewe model. Maintaining pregnancy during a time
of maternal growth and development depletes maternal body stores and adding
nutrient restriction, further limits nutrients available to the fetus. On day 90,
under these extreme circumstances, total placentome weight, mean placentome
weight and gross anatomy were not different between control and nutrient
restricted. By day 130 of gestation, there was a modest reduction in fetal weight.
Only a modest reduction in fetal weight compared to the expected extreme
reduction may be a result of placental compensation. The placental parameters
were not different and similar changes in placentome type from mostly A type
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placentomes to a mix of A, B, C and D type placentomes had occurred by day
130. It was further noted that cotyledonary capillary density increased which
increases vessel surface area and cotyledonary number density increased as
gestation advanced while caruncular capillary density decreased (Luther et al.,
2007). The authors noted that fetal growth was restricted in the nutrient
restriction group; however, it was speculated that fetal development would have
been further perturbed without proliferation of the cotyledonary capillaries (Luther
et al., 2007).

Somatotrophic Axis
Fetal Growth Axis
Growth hormone (i.e., somatotropin) is detected as early as day 43 and is
at least 20 times higher in concentration in fetal circulation compared to that
observed in adults and is secreted in a biphasic pattern (Stokes and Boda, 1968;
Basset and Gluckman, 1986; Polkowska et al., 1995). The concentration of
growth hormone is high between day 60-70 of gestation (148 ng/ml) falling to 49
ng/ml by day 100 through 110 and reaching a second peak concentration of 150
ng/ml between day 130 and 140 (Gluckman et al., 1979a). However, growth
hormone concentration drops 80% within one hour of birth such that neonatal
growth hormone concentration plummets to less than 10 ng/ml (Gluckman et al.,
1979a; Bassett and Gluckman, 1985). The regulation of fetal growth hormone
secretion is not known, but is believed to be, in some part, regulated by the
somatotrophic axis. Growth hormone synthesis and secretion in the fetus is
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regulated by growth-hormone-releasing hormone and somatostatin, but the
regulation of the secretion of these two hormones in the fetus is not yet known.
Both hormones are synthesized in the hypothalamus and detectable by mid
gestation in the sheep (Polkowska et al., 1995). Growth-hormone-releasing
hormone administration to the fetus results in an increase in growth hormone
secretion (De Zeghner et al., 1989). Somatostatin inhibits the release of growth
hormone when administered to the fetus and removal of somatostatin allows for
growth hormone to rise (Gluckaman 1979b). While growth hormone secretion is
regulated during fetal development it does not stimulate fetal growth because it
does not appear to stimulate insulin like growth factors (IGF) which are the major
hormones responsible for stimulating fetal growth. Growth hormone is present
but the receptor is expressed at very low levels until right before birth (stimulated
by the glucocorticoid surge; Gluckman and Pinal, 2003).
Insulin like growth factor-I is the predominant growth factor late in
gestation that stimulates growth along with IGF II, and both are produced by the
fetal liver and other tissues during fetal development (Lok et al., 1996). Both
IGF-I and IGF-II elicit a growth response by binding to the IGF-I receptor. Insulin
like growth factor-II receptor is a clearance receptor decreasing the concentration
of IGF-ll in circulation but binding does not elicit a response (Gluckman and
Pinal, 2003). In fact, birth weight and crown-rump length are highly correlated to
IGF-I (Bauer et al., 1998). During gestation the main regulator of IGF-I is glucose
availability (Oliver et al., 1996). Nutrients detected in fetal blood obtained after a
four hour infusion of IGF-I around day 130 of gestation suggest fetal growth is
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promoted. Insulin like growth factor-I infusion resulted in a decrease in fetal
amino acid nitrogen concentrations, a trend for an increase in amino nitrogen
uptake and a decrease in fetal urea production (a measure of amino acid
oxidation) which all suggest an increase in fetal growth (Harding et al., 1994). In
a similar study in which fetal infusion of IGF-I occurred from day 120 to 130 of
gestation an increase in internal organ weights were observed in treated fetuses.
There was an increase in the weight of the liver, heart, kidney, and spleen and an
increase in length of some of the long bones, but no observed difference in
muscle weight (Lok et al., 1996).
Postnatal Growth Axis
Unlike what is observed during fetal development, growth hormone
regulates the secretion of IGF-I and is therefore the hormone that stimulates
postnatal growth (Gluckman et al., 1986). Growth hormone secretion is
regulated by growth hormone releasing hormone, somatostatin and partially by
ghrelin. Growth hormone releasing hormone stimulates both synthesis and
secretion of growth hormone while, somatostatin inhibits secretion but not
synthesis. Ghrelin which is produced by the stomach, intestine and central
nervous systems has also been found to stimulate the synthesis and secretion of
growth hormone at the level of the hypothalamus and pituitary (Gluckman et al.,
1986; Anderson et al., 2004). In sheep, growth hormone secretion is
asynchronous and episodic and the pulse patterns are different between males
and females. A higher pulse amplitude and higher baseline are typical
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characteristic for a male pattern compared to lower amplitudes with a lower
baseline level for females (Gatford et al., 1997).
Insulin like growth factor-I (i.e., somatomedin C) and IGF-II (i.e.,
somatomedin A) are produced throughout the body with the liver being the main
source. Their secretion is stimulated by growth hormone, other hormones and
other substances (i.e., insulin, steroids, interleukins and amino acids). Insulin
like growth factor-I is the more potent growth stimulator and promotes growth in
both a paracrine and endocrine manner (Douglas et al., 1991). Insulin like
growth factors bind to insulin like growth factor binding proteins in the blood,
which act as a storage mechanism since free IGF-I is not stored in any organ or
tissue. The concentration of total IGF-I in plasma is 100 to 1000 mg/ml which is
well above what is required to elicit a response, but this includes all IGF-I (bound
and free; Gluckman et al., 1987). In sheep, fetal levels of IGF-I are similar to
those observed in the adult (120 ng/ml). However, at birth IGF-I concentrations
rapidly increase to about 400 ng/ml and remain elevated until about day 50, at
which time they decrease to around adult levels. Insulin like growth factor-II on
the other hand drops dramatically the last five days of gestation to the levels
observed at birth (795 ng/ml to 160 ng/ml) and remains at about the same level
from birth through adulthood (Gluckman and Butler, 1983).

Intrauterine Growth Restriction
Since the original link was made between birth weight and adult onset
disease, the fetal origins of adult disease has been extensively examined using
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animal models. Several animal models have been developed to study fetal
programming, utilizing maternal dietary manipulation, hyperthermia, hormone
administration, uterine artery ligation and embolization of the placenta to
establish a detrimental uterine environment (Wallace et al., 2001; Jensen et al.
2002; Armitage et al. 2004; Wu et al. 2004; Wallace et al. 2005; Wu et al., 2006).
Dietary manipulation to the dam has been the most widely used experimental
paradigm for investigating programming. The specific regimens for applying
dietary restriction are numerous, as the specific details and duration of dietary
restrictions used are numerous (Wu et al., 2004; Wu et al., 2006; Wallace et al.,
2005). The majority of fetal growth restriction models work by inducing placental
insufficiency. The link between altered placental growth, vascular development,
nutrient transport, placental metabolism and the partitioning of nutrients between
the dam and the fetus are all speculated to impact programming of the fetus and
adult adaptation to the environment.
The majority of fetal programming/intrauterine growth restriction studies
have been developed and performed in rodents, most likely a result of cost and
availability. However, a few models utilizing the ewe have been developed and
extensively studied. The ovine is one species that is utilized as an animal model
for humans for a few reasons. First, they normally only have singles or twins
compared to pigs and rodents that have larger litters. Second, nutrient restriction
alters nutrient availability to the fetus. In pigs, the dam has the remarkable ability
to mobilize maternal body stores to compensate for nutrient intake. In fact, a
moderate restriction does not result in intrauterine growth restriction (Wu et al.,

28

2006). Third, a lamb fetus is large enough to instrument allowing for collection of
data from a fetus in a conscious female. These models include the nutrient
restriction, overnourished adolescent ewe, maternal heat stress and placental
embolization.
Maternal Nutrient Restriction
Nutrition is speculated to be the major factor influencing placental and
fetal growth and development. As a result, maternal nutrition plays a critical role
in proper development of the placenta and therefore nutrient availability to the
developing fetus. Evidence suggesting such a strong role for the effects of
maternal nutrition is found naturally and experimentally. Range animals are
subjected to forages which are affected by seasonal climate change and severe
weather. In the western United States, ewes are maintained on less than 50% of
the daily nutrients recommended by the National Research Council. Lambs that
were born to ewes that were exposed to these harsh conditions appeared to
have compromised health (Thomas and Kott, 1993; Vonnahme et al., 2003; Wu
et al., 2004). Nutrient restriction in experimental models can vary in the severity,
duration and period of pregnancy (i.e., early, mid or late gestation) of the
restriction.
The majority of maternal nutrient restriction models impose restriction
between day 28 and 80 of gestation. Some nutrient restrictions are extend for
longer periods of time, until fetal tissue collection (day 90 or 135). The level of
nutrient restriction is highly variable and ranges from 30% to 50% of the daily
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nutrient requirement. Fetal weight is reduced approximately 32% by maternal
nutrient restriction from day 28 to day 80 regardless of the level of nutrient
restriction (30% or 50%; Vonnahme et al., 2003; Kwon et al., 2004;). However,
others have observed that nutrient restriction did not have an effect on lamb
weight at term (Heasman et al., 1998; Ford et al., 2007). When nutrient
restriction was extended to gestational day 135 only a 15% reduction in fetal
weight was observed (Osgerby et al., 2002; Kwon et al., 2004; Osgerby et al.,
2004).
Surprisingly, even though nutrient restriction was applied during the time
in which the placenta is undergoing rapid growth to day 78, no difference in
placental weight was observed (Vonnahme et al., 2003). However, by term total
placental weight, as well as fetal cotyledonary tissue weight was greater in the
treated group compared to the controls. This increase in weight may be
associated with a decrease in the number of A type placentomes and an
increase in the number of B and C type placentomes observed at term (Heasman
et al., 1998; Osgerby et al., 2004). Information available on umbilical blood flows
are variable in that some research shows an increase while others show no
change (Reynolds et al., 2005). Nutrient flux across the placenta appears to be
altered by nutrient restriction during early and mid gestation in the ewe. Glucose
concentration and 11 of 23 amino acids measured in fetal circulation were
decreased in fetuses gestated by ewes subjected to a nutrient restriction
compared to those gestated by controls (Osgerby et al., 2002; Kwon et al.,
2004). Maternal nutrient restriction appears to alter placental function early in
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gestation which results in limited fetal growth. However, upon removal of the
restriction the placenta appears to compensate by its altering growth.
Overnourished Adolescent Ewe Model
The overnourished adolescent ewe model utilizes the hierarchy of nutrient
partitioning to limit fetal placental growth. Normally, nutrition is shunted to the
fetus to promote proper growth, but when the dam is still growing (i.e.,
adolescent) maternal growth takes priority above fetal growth which means
nutrients are partitioned to maternal growth at the cost of the gravid uterus. The
majority of the reduction in fetal and placental weight comes from altered nutrient
partitioning. Overfed growing adolescents gain at least four times as much
weight (200-350 g/day) compared to those fed a moderate diet (50-85 g/day).
The increase in weight comes from an increase in fat storage and maternal body
weight gain (Wallace et al., 2006b). The results of these studies show a
reduction of 33% in the overall feto-placental mass at birth compared to
moderately fed controls which correlates to a 29% reduction in birth weight
(Wallace et al., 2001). Fetuses from overnourished ewes are normally small for
their gestational age and born premature.
Overnourishing adolescent ewes reduces uterine blood flow and placental
function which limits nutrient availability to the developing fetus and results in
small lambs at birth. Nutrients available for transport are reduced as a result of a
decrease in uterine blood flow by approximately 36% compared to control. When
fetal weight is taken into consideration the uterine blood flow is proportionally the
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same, but umbilical blood flow per gram of fetal weight is reduced by 15% which
is consistent with the suggestion that uterine blood flow regulates fetal growth
(Wallace et al., 2002b). In this model established placentomes not only have a
smaller mass, but the actual number established per placenta is reduced
compared to moderately fed controls (Wallace et al., 2001). Overnourishing
adolescent pregnant ewes reduced umbilical amino-acid uptake for 12 of 16
amino acids measured and glucose. The decreased uptake was speculated to
result from a reduction in placentome total surface area because when placental
uptake was expressed on a placental weight basis, no difference in glucose
uptake was observed (Wallace et al., 2002a; Wallace et al., 2004). The
reduction in fetal weight, placental weight and nutrient transfer may be a result of
a reduction in angiogenesis within the placenta or uterine blood flow. On day 81,
(the point when placental growth reaches a plateau but angiogenesis continues
to compensate for the continual rapid growth of the fetus) expression of
angiogenic factors including vascular endothelial growth factor, angiopoietin 1,
angiopoietin 2 and nitric oxide synthase 3 were decreased by almost 50% in
overnourished adolescent ewes compared to those that were moderately fed
(Redmer et al., 2005).
Maternal Heat Stress Model
In sheep, increasing the external ambient temperature 20 degrees during
the middle to final portion of pregnancy results in placental insufficiency and poor
fetal development. The general procedure is to place ewes in a hot room around
day 35 of gestation, the time when the rapid growth phase of the placenta starts,
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and remove the ewes approximately 60 days later. The duration of exposure to
high temperature per day varies among experiments and ranges from only nine
hours per day to a constant 24 hour per day exposure. High ambient
temperatures were considered 40°C compared to controls, 18-20°C, and the
humidity ranged from 30-40% (Thureen et al., 1992; Galan et al., 1999; Bell et
al., 2003). During periods of heat exposure, ewe rectal temperature averages
about 40.3°C which is one degree higher than those housed at control
temperatures (Bell et al., 1989). Exposing a pregnant ewe to extreme ambient
temperature reduces fetal weight in a time-dependent manner. In all cases, high
ambient temperature exposure resulted in a reduction of at least 17% to 50% in
fetal body weight compared to those fetuses collected from ewes housed in a
thermoneutral temperature.
A 54% reduction in placental weight was observed following exposure to
extreme ambient temperature which is most likely a result of a decrease in
placentome weight (Bell et al., 1989; Thureen et al., 1992). Uterine blood flow is
not different in pregnant ewes subjected to either a thermoneutral or
hyperthermic environment; however, when scaled to either fetal or placental
weight (uterine blood flow/weight) uterine blood flow is increased in those ewes
exposed to higher ambient temperatures suggesting that uterine blood flow is not
reduced in relationship to metabolic demands of the placenta and fetus (Thureen
et al., 1992; Regnault et al., 2003). Nutrient delivery via uterine blood flow may
not be limiting but, a reduction in umbilical blood flow may be the cause for a
decrease in nutrient extraction. Heat stress led to a reduction in fetal glucose
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concentration, fetal uptake of glucose and overall extraction of glucose by the
gravid uterus (Regnault et al., 2003). Heat stressed pregnant ewes exhibited
altered placental expression of angiongenic factors. In maternal caruncular
tissue of heat stressed ewes, expression as well as protein concentration of
placental growth factor (PlGF) increased, but no changes were observed for
vascular endothelial growth factors. In fetal cotyledonary tissue, vascular
endothelial growth factor expression and protein decreased, PlGF was not
altered by hyperthermic conditions (Regnault et al., 2003). In this model, the
maternal supply of nutrients appears not to be limiting fetal growth, but a limited
growth and development of the fetal side of the placenta appears to be the
culprit.
Placental Embolization
Placental embolization is used to study the fetal growth axis in growth
restricted fetuses late in gestation. Around day 110 of gestation, pregnant ewes
undergo surgery to place catheters in the maternal uterine artery and to
chronically catheterize the fetus. Around two days post surgery microspheres
between 25 and 50 µm in size are injected into the maternal artery catheters
twice daily for two days. The duration and amount of microspheres injected daily
is then altered based on fetal growth (as measured by a growth catheter placed
around the chest of the fetus) and when fetal growth is slowed or stopped for two
days then embolization is stopped. Injection of microspheres creates a placental
insufficiency limiting blood flow to the placenta and limits the area available for
nutrient exchange. In all cases, embolism resulted in a reduction in fetal weight
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ranging from 15% to 38% (Jensen et al., 1999; Bloomfield et al., 2002; Bauer et
al., 2003; Louey et al., 2005). In the only study that measured placental weight,
embolization led to a 30% reduction in placental weight at birth (Louey et al.,
2005). Alterations in placental weight are of limited value, since the majority of
placental growth is during the first 80 days of gestation. However, it is not
surprising that placental weight decreased because it requires nutrients from
maternal blood to meet its metabolic demands.

Impact of Intrauterine Growth Restriction
The above described models create forms of placental insufficiency and
altered nutrient delivery which may lead to temporary or permanent alterations in
fetal organ development and function. In intrauterine growth restricted fetuses,
blood is shunted to the brain at the expense of other organs including the heart
and liver. In humans, for example, the reduced abdominal circumference
observed in intrauterine growth restriction may be an indicator of reduced liver
growth and development. In fact, smaller abdominal circumference at birth has
been correlated with elevated concentrations of total and low density lipoproteins,
cholesterol and fibrinogen in the blood, which are risk factors for adult
cardiovascular disease. Barker et al. (1995) utilized abdominal girth as way to
assess liver development and found that small abdominal circumference at birth
was correlated with an increased incidence of coronary heart disease regardless
of social status, weight, smoking or alcohol consumption. Below is a table that
summarizes general outcomes observed with different models of fetal growth
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restriction. Included are measures of fetal development and organ weights
relative to fetal body weight and how they are impacted by models of intrauterine
growth restriction (Table 3).
The data presented in the table are summarized from a number of studies
and therefore, variation in the general summary may be a result of the exact
protocol used to induced fetal growth restriction. All of the studies led to a
reduced fetal size as measured by fetal weight, crown-rump length and
abdominal girth. However, the information available on fetal organ growth is
limited and sometimes contradictory. For example, maternal under nutrition
appears to have no effect on abdominal girth at day 78 of gestation but
abdominal girth is reduced by day 135 (Osgerby et al., 2002; Vonnahme et al.,
2003). Similarly, liver weight relative to fetal weight is increased at day 78 but no
difference is observed by day 135. Data may be influenced by the duration and
timing of nutrient restriction. Until day 78, fetal growth is very slow while
placental growth is quite rapid. However, data collected on day 135 is influenced
by continual nutrient restriction through the placental growth phase and through
the rapid fetal growth phase. Heart weight and ventricular wall thickness may be
harder to explain because it has been speculated that heart development is
affected by other vascular measures. Fetuses gestated by dams, nutritionally
restricted to 50% of the control group from day 28 to day 78 of gestation, had an
increased ventricular weight per gram of fetal body weight (Vonnahme et al.
2003). A hypertrophic increase in the fetal ventricular wall has been suggested
to result from an increase in ventricular afterload which is indicative of an
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increase in peripheral arterial pressure (Samson et al. 2000; Vonnahme et al.
2003). A mechanism by which placental vascular resistance may result in
altered fetal heart development has been postulated by Vonnahme et al. (2003).
In sheep, intrauterine growth restriction can lead to an increased placental
vascular resistance (Vonnahme et al. 2003).
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Maternal Nutrient Restriction
Fetal Weight
Crown-rump Length
Abdominal Girth
Brain Weight
Liver Weight

Heart Weight

▼ at all stages of gestation
▼ at all stages of gestation
No Change at day 78 of gestation (period of placental
growth)
▼ by day 135 of gestation (during the period of rapid fetal
growth)
No Change
▲ at day 78 of gestation (period of shunted placental
growth)
No difference by day 135 (placenta is able to compensate
and increase nutrient flux to the developing fetus increasing
liver growth)
▲ Right and left ventricular wall weight at day 78 of
gestation
▼ in total heart weight at day 135

Overnourished Adolescent Ewe
Fetal Weight
Crown-rump Length
Abdominal Girth
Brain Weight
Liver Weight
Heart Weight

▼ during fetal development and at birth
▼ during fetal development
▼ during fetal development
No change in two out of three studies (one study found an
increase)
No change
No change

Maternal Heat Stress
Fetal Weight
Crown-rump Length
Brain Weight
Liver Weight
Heart Weight

▼ during fetal development
No difference was observed when heat stress was applied
early in gestation
▼ when heat stress was induced around the time of rapid
fetal growth
No change in two out of three studies (one study found an
increase)
No difference was observed in two out of three studies (the
one study that detected a decrease started applying heat
stress late in gestation
No change

Placental Embolization
Fetal Weight
Crown-rump Length
Abdominal Girth
Brain Weight
Liver Weight
Heart Weight

▼ following embolization
▼ following embolization
▼ following embolization
No change
No change was observed in two out of three studies but one
of three observed a reduction in fetal liver weight
No change was found in two of four studies
▼ in heart weight in two out of four studies
▼ Right and left ventricular wall thickness

TABLE 3. Impact of nutrient restriction models on fetal components and organ
weights.
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Statement of the Problem
The use of animal models has allowed extensive investigation in the field
of fetal programming, specifically critical assessment of the effect of uterine
environment (i.e. secretion, timing and space) on embryonic development, fetal
growth and ultimately adult life. Using animals models, researchers have been
able to link a deleterious uterine environment during specific stages of fetal
development to altered development and function (i.e., programming) of the
cardiovascular, respiratory, endocrine, reproductive, immune and central nervous
systems as well as the function of the kidneys and liver and bone density
(Godfrey and Barker, 2000; Wu et al., 2004). However, the majority of studies
conducted in the area of fetal programming have been limited to only the effects
of a negative uterine environment. Few studies have tried to ameliorate the
impact of experimentally induced intrauterine growth restriction by administering
growth promoters, but again the basis of the experiment is to first inhibit fetal
growth. However, the growth that is stimulated is only transient.
Therefore, we endeavored to investigate a recent observation from our
laboratory that reported that a single injection of growth hormone given at
breeding results in lambs that are ~10% larger at birth (Costine et al., 2005).
Determining how a single injection of growth hormone at breeding promotes
growth throughout gestation leading to heavier lambs 145 days later may
ultimately change how we think about fetal programming. The present studies
were designed to specifically address three important questions. First, how is the
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early uterine environment altered by a single injection of growth hormone given
that this environment can potentially program the developing embryo? Second,
how does the placenta that develops from the conceptus exposed to an altered
uterine environment become more efficient and able to transport more nutrients
to the developing fetus late in gestation when fetal demand for nutrients
increases? Third, do lambs born to ewes treated with growth hormone, have
altered growth and development, including programmed alterations of the growth
hormone axis of the lambs born to ewes treated with growth hormone?
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Abstract
We have shown that an injection of sustained release growth hormone
(GH), given just prior to breeding, results in lambs that are 10% heavier at birth,
with an altered body composition as evidenced by an increased abdominal girth,
but no difference in crown-rump length. The mechanisms by which these
differences occur from a single periconceptional injection are not yet known.
Therefore, the objective of this experiment was to determine the effect of an
injection of GH given prior to breeding on the composition of the uterine
environment at the time of blastocyst formation and the trophectoderm to inner
cell mass ratio. Ewes were synchronized with two injections of prostaglandin
given eight days apart. On the day of the second injection, ewes were randomly
assigned to be given an injection of sustained release GH or remain as controls
and penned with a ram. On day 6.5 following breeding embryos were surgically
collected by flushing each oviduct. Prior to surgery a jugular blood sample was
taken to determine plasma progesterone and urea concentrations. The uterine
content of urea, prostaglandin F2α, prostaglandin E2, transforming growth factor
ß-1 (TGF ß), nitric oxide metabolites and total protein were measured. Collected
embryos were differentially stained to calculate a trophectoderm to inner cell
mass ratio. The uterine content of urea in the GH group was lower (p < 0.05)
than that of the control group. There was a trend for TGF ß to be increased in
the GH treated group compared to control (p=0.07). There was no difference in
the total uterine content of prostaglandin F2α, prostaglandin E2, protein or nitric
oxide metabolites. The concentration of progesterone and insulin in maternal
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plasma was greater in the treated group compare to controls, but blood urea
nitrogen was not different between groups. The trophectoderm to inner cell mass
ratio or the total number of blastomeres was not different between treatment
groups. Thus, we suggest that the observed difference in fetal development
following periconceptional growth hormone administration just prior to breeding
may be a result of an alteration in the uterine environment, which may alter the
cellular program of the conceptus and later development, beyond the embryonic
stage.
Key Words: growth hormone, uterine environment, embryo
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Introduction
Exposure to an insult or a stimulus during critical periods of development
can result in long lasting and possibly permanent physiological alterations, a
phenomenon known as programming (Godfrey & Barker, 2000). The uterine
environment in which the conceptus and developing fetus are exposed to has
been extensively studied. Particularly in the sheep, studies range from the
effects of early uterine environment through late gestational treatments.
However, the majority of these studies focus on negatively impacting fetal growth
and development and only a limited number of studies have tried to promote fetal
growth and development.
It has been understood for at least 50 years that altering the early
embryonic environment can greatly impact embryonic growth and survival
(Moore and Shelton, 1964). The success of embryo transfer drops below 10% if
the embryos are transferred to a uterine environment that is more than 48 hours
ahead or behind that from which the embryo was collected (Rowson and Moor,
1966). The stage of embryonic development also impacts the success of
embryonic survival as a time-dependent increase. Specifically as the age of the
embryo increased the rate of survival increased (Moore and Shelton, 1964;
Rowson and Moor 1966).
Embryo transfer into an advanced uterine environment has been found to
alter early fetal development (Kleeman et al., 1994; Young et al., 1996). Fetal
growth was increased in ewes exposed to progesterone during the first six days
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of gestation (Kleeman et al., 1994). Similarly, Young et al. (1996) found that
fetuses derived from embryos transferred to an advanced uterine environment
were 42% heavier by gestational day 21. Recently, we demonstrated that a
single injection of growth hormone given at or just prior to breeding increases
birth weight by 10 (Costine et al., 2005).
Therefore, the objective of this experiment was to determine the effect of
an injection of sustained release growth hormone given just prior to breeding on
the composition of the uterine environment at the time of blastocyst formation.
Additionally the ratio of trophectoderm to inner cell mass is altered and the total
number of blastomeres was determined to possible alterations in embryonic
growth.

Materials and Methods
Ewes (n=59), primarily of Suffolk breeding, from the West Virginia
University farm were used for the experiment. All procedures were approved by
the West Virginia University Animal Care and Use Committee (ACUC No. 050805).
Estrus was synchronized by administering two injections of 20 mg (i.m.) of
prostaglandin F2α (Lutalyse, Pfizer; New York, NY) eight days apart. Ewes were
randomly assigned to either a control group (n=35) or a growth hormone treated
group (n=24). The growth hormone treated group received a single 500 mg
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injection of sustained release recombinant bovine growth hormone
subcutaneously (Posilac; Monstanto, St. Louis, MO) at the same time as the
second prostaglandin F2α injection. This dose was previously reported to
increase uterine luminal insulin like growth factor-I (IGF-I) 4-fold on day 7 of
gestation and result in larger lambs at birth (Costine et al., 2005). Ewes were
penned with a fertile ram fitted with a marking harness and ewes were checked
twice daily for the appearance of new marks which occurred two to three days
(day 0) following the second prostaglandin F2α injection.

Embryo Collection
On day 6.5, ewes underwent surgery for embryo collection. Briefly, all
ewes were anesthetized and maintained on a 10% ketamine drip (Vedco;
Columbus Serum, Columbus, OH) and 50 mg/ml sodium pentobarbital to effect
(Sigma; St. Louis, MO). A midventral incision was made in the abdominal wall to
expose the uterus and the oviducts. The right and left uterine horn were flushed
separately as follows. A small incision was made at the base of the uterine horn
and a glass cannula was inserted into uterine horn. A blunted needle, attached
to a glass syringe, was inserted into the oviduct through the infundibulum.
Pinching off around the needle, 10 ml of phosphate buffered saline (pH 7.4) was
flushed through the oviduct and uterine horn to the glass cannula and collected in
petri dish. Embryos were removed from the flushings and processed for
immunosurgical lysis. Flushings were centrifuged at 2,000 x g to pellet any

46

cellular debris and the remaining flushing was aliquoted into microcentrifuge
tubes and stored at -20°C until further analysis.

Immunosurgical Lysis
Immnunosurgical lysis allows for the differential staining of the two main
cell types of the blastocyst, the trophectoderm and the inner cell mass. Embryos
were stained using a procedure previously used to stain pig embryos but
modified to allow for proper staining of sheep embryos (Rivera et al., 1996).
Embryos were incubated in Tyrode’s Solution (0.8% NaCl, 0.4% polyvinyl
pyrrolidone, 0.24% CaCl2·H2O, 0.1% glucose, 0.02% KCl, and 0.01%
MgCl2·6H2O; pH 2.5) for 45 s at 39°C to remove the zona pellucida. Embryos
were then rinsed three times in modified phosphate buffered saline (mPBS; 1%
penicillin-streptomycin, 0.4% BSA, 0.0036% sodium pyruvate and 0.0023% Lglutamine). Embryos were then incubated with 10 nmol/L trinitrobenzene
sulfonic acid (Sigma, St. Louis, MO) for 30 min on ice. Trinitrobenzene sulfonic
acid labels the surface of the trophectoderm cells with trinitrophenol groups.
Embryos were then washed three times in mPBS and then placed in 0.1 mg/ml
anti-dinitrophenol (Sigma, St. Louis, MO) for 30 min at 39°C. Anti-dintrophenol is
antiserum against dintrophenol and cross reacts with trinitrophenol groups which
form on the surface of the trophectoderm following exposure to trinitrobenzene.
Embryos were then washed three times in mPBS and placed into a mPBS
solution containing a 1:5 dilution of guinea-pig complement (Sigma, St. Louis,
MO) and 0.01mg/ml propidium iodide (Sigma, St. Louis, MO) for 30 min at 39°C
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in the dark. Guinea pig complement interacts with the antibodies attached to the
trophectodermal cells and lyses the trophectoderm cells allowing propidium
iodide into the cell. The nuclei of these cells are thus stained red. Embryos were
then washed two times in mPBS before being incubated for 15 min in the dark at
39°C in 0.05 mmol/L Hoechst 33258 in mPBS (Sigma; St. Louis, MO). After 15
min embryos were moved into a 0.05 mmol/L Hoechst 33258 in 100% ethanol
protected from light and incubated overnight at 4°C. Hoechst can cross all
membranes and stains nuclei blue. Therefore, the nuclei of the inner cell mass
appear blue, and the nuclei of the trophectoderm appear pink because they are
stained with both propidium iodide and Hoechst (Figure 3). Embryos were then
incubated in 100% ethanol for 30 mins at 4°C. Following fixation in ethanol
embryos were transferred to a slide with 5 µl of glycerol and covered with a glass
cover slip.
The number of inner cell mass and trophectoderm cells for each embryo
(n=27 control, n=17 GH) were counted using an inverted microscope (Nikon
TE2000) equipped with a mercury vapor lamb and a UV filter set which
illuminated the embryo at 380 nm, which is the wave length of excitation for both
dyes and a barrier filter at 420 nm. The two types of nuclei were counted by two
different counters independently and these numbers were averaged together.
The total number of cells was calculated by adding all the red and blue cells
together.
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FIGURE 3. Differential staining of a blastocyst collected on day 6.5 by
immunosurgical lysis. The inner cell mass cells are stained blue while the
trophectoderm is stained pink.

Uterine Flushings
Prostaglandins
Prostaglandin E2 and prostaglandin F2α were analyzed by commercially
available EIA (Cayman Chemical Company; Ann Arbor, MI) and validated in our
laboratory to detect prostaglandins in uterine flushing.
TGFβ-1
The TGFβ-1 in the uterine flushings was determined using a human
TGFβ-1 Duo Set enzyme linked immuno-sorbent assay (ELISA) kit (R&D
Systems, Minneapolis, MN) and ELAST® ELISA amplification system
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(PerkinElmer Life Sciences, Boston, MA) following manufacturers’ instructions
and altered for uterine flushings (Holaskova, 2007). Briefly, flat bottom 96 well
Nunc-Immuno plates with MaxiSorp surface treatment (Fisher Scientific, PA),
were coated with capture antibody (mouse anti- TGFβ-1; 2 µg/mL) and incubated
overnight at room temperature. After a wash, plates were blocked by adding the
blocking buffer for a minimum of 1 hour, washed, and 100 µl of acid-treated
uterine flushing (1N HCl for TGFβ-1 activation, 1.2 N NaOH/0.5 M HEPES for
neutralization), or standards were added in duplicate. An eight-point standard
curve consisted of 2-fold serial dilutions of recombinant human TGFβ-1, starting
at 125 pg/mL for the high stanard. Plates were incubated overnight at 4°C,
washed, and the detection antibody was applied (biotinylated chicken anti-human
TGFβ-1, 300 ng/mL) for 2 hours at room temperature. Streptavidin conjugated to
horseradish peroxidase was added to each well, incubated for 20 min at room
temperature in the dark, washed, and was followed by substrate solution (H2O2
mixed 1:1 with tetramethylbenzidine, R&D Systems, Minneapolis, MN) for 20 min
at room temperature in the dark. A biotinyl-tyramide amplification step was
inserted into the ELISA procedure (ELAST® ELISA Amplification System; Perkin
Elmer, Boston, MA), which increased the sensitivity to 2 pg/mL. The reaction
was stopped with 2 N H2SO4 (50 µL/well) and plates were analyzed with a
microplate spectrophotometer (SPECTRAmax® PLUS384,Molecular Devices,
Sunnyvale, CA). Readings at 540 nm were subtracted from those at 450 nm for
the wavelength correction, and plotted against the standard curve using the
SoftMax®Pro software (version 4.6, Molecular Devices, Sunnyvale, CA). The
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unknown fluid validation protocol resulted in detection of 82% of recombinant
TGFβ-1 in the uterine flushing samples. Duplicate values with less than a 20%
coefficient of variation were accepted for statistical analysis.
Urea
The urea concentration in uterine flushing and maternal plasma were
determined by a commercial assay kit for measuring urea in biological samples
(BioAssay Systems; Hayward, CA). Duplicate values with less than a 20%
coefficient of variation were accepted for statistical analysis.
Nitric Oxide Metabolites
One way of assessing nitric oxide production is to measure its two
metabolites nitrite (NO2-) and nitrate (NO3-). Nitrite in uterine flushing was
determined using a commercially available assay (Griess Reagent System;
Promega; Madison, WI). The concentration of nitrite and nitrate in uterine
flushing was subsequently determined using a commercial assay kit in biological
samples (BioAssay Systems; Hayward, CA) in which nitrate is reduced to nitrite
and total nitrite is determined.
Protein
The Bradford assay was used to determine protein content in uterine
flushing. A standard curve was generated using BSA (Pierce, Rockford, IL) and
Coomassie blue dye (Pierce, Rockford, IL), which upon binding to protein
changes absorbance from 465 nm to 598 nm. The absorbance at 598 nm is
directly proportional to the amount of protein in the sample. Duplicate values
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with less than a 20% of coefficient of variation were accepted for statistical
analysis.
Maternal Plasma
Progesterone
Progesterone concentrations from jugular plasma samples were
determined using RIA (Sheffel et al., 1982) with a sensitivity of 100 pg/ml and
intra- and interassay CV of 4.3 and 7.7%, respectively.
Insulin
Jugular plasma insulin was measured using an insulin RIA kit (Diagnostic
Products Corporation, Los Angeles, CA) with a sensitivity of 0.05 nM and
intraassay CV of 3.1%. The assay was validated to measure sheep insulin in our
laboratory. Briefly, plasma dilutions from two ewes were assayed separately for
insulin and found to be parallel with the standard curve (Lemley et al., 2008a)

Statistical Analysis
The effect of periconceptional growth hormone treatment to the dam on
the concentration of protein, urea, prostaglandin E2, prostaglandin F2α, TGF ß1
in uterine flushings was analyzed by analysis of variance, utilizing the general
linear models procedure in SAS. The effect of periconceptional growth hormone
treatment on maternal progesterone concentration was analyzed by analysis of
variance, utilizing the general linear models procedure in SAS. The correlation
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between trophecoderm to inner cell mass ratio and uterine flushing components
was determined using the correlation procedures of SAS.

Results
Periconceptional GH treatment increased maternal progesterone (p <
0.05; Figure 4) and insulin (p < 0.05; Figure 5) concentrations. However, GH
treatment did not alter maternal blood urea nitrogen (51.03 ± 3.11 mg/ml).
Periconceptional growth hormone treatment did decrease uterine luminal
urea (p < 0.05) content on day 6.5 of pregnancy (Figure 6). There was a trend
for an increase in TGF-ß1 (p = 0.07; Figure 7). Growth hormone treatment did
not alter uterine content of prostaglandin F2α (1677.02 ± 97.23 ng/ml),
prostaglandin E2 (763.48 ± ng/ml), nitrite and nitrate (86.35 ± 4.11 µM) or nitrite
(7.39 ± 0.41 µM). Overall GH treatment did not alter the trophectoderm to inner
cell mass ratio (4.26 ± 0.60) or the total number of blastomeres per embryo
(40.38 ± 3.37).
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FIGURE 4. Maternal progesterone concentration on day 6.5 of gestation in
control ewes and those treated with a periconceptional GH injection. * Indicates
a treatment difference p < 0.05.
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FIGURE 5. Maternal insulin concentration on day 6.5 of gestation in control ewes
and those treated with a periconceptional GH injection. * Indicates a treatment
difference p < 0.05.
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FIGURE 6. Uterine luminal urea content on day 6.5 of gestation in control ewes
and those treated with a periconceptional GH injection. * Indicates a treatment
difference p < 0.05.
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FIGURE 7. Uterine luminal TGFß-1 content on day 6.5 of gestation in control
ewes and those treated with a periconceptional GH injection. * Indicates a
treatment difference of p < 0.05.
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Discussion
The concentration of progesterone and insulin in the GH treated group
were greater than the concentration observed in the control group. Progesterone
administration is one tool used to study the impact of the uterine environment on
embryonic development. Progesterone treatment during early pregnancy has
been shown to increase both fetal mass and crown-rump length later in
gestation. Fetal growth was increased in ewes exposed to progesterone from
days 1-3, 3-6 or 1-6 of gestation (Kleemann et al., 1994). Progesterone
treatment starting on day one had the greatest impact on fetal growth in that both
fetal mass and crown-rump length increased (Kleemann et al., 1994).
Progesterone exposure on only days 3-6 increased fetal mass, but not to the
extent of that observed when treatment was started on day one, and fetal crownrump length was not different (Kleeman et al., 1994). Embryos transferred into a
recipient uterine environment on day 3, which was previously primed by
progesterone administration starting on days 1-3, had approximately 7% greater
fetal mass on day 76 compared to control fetuses (Kleemann et al., 1994). Day 3
embryos transferred to a more advanced uterine environment on (i.e., a day 6
uterine environment) for three days before being transferred back into their
original uterine environment (i.e., now a day 6) were found to be 42% heavier at
day 21 of gestation (Young et al., 1996). Maxfield et al. (1998) utilized the same
transfer methods in which day three embryos were transferred to a uterine
environment advanced by three days (i.e., day 6 environment), for three days,
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and then transferred back to a day six environment. The fetuses collected from
this experiment had altered muscle development. While there was no difference
in fetal weight or crown-rump length, those embryos transferred to an
asynchronous environment had a greater number of muscle fibers compared
tothose maintained in the synchronous environment (Maxfield et al., 1998). This
indicates that only a small change in the embryonic environment, for a short time,
can result in “fetal programming.”
The observed elevation in progesterone concentrations in ewes treated
with growth hormone may be explained by an increase in production of
progesterone, a decrease in catabolism of progesterone or a combination of
both. Recent studies in the ewe and dairy cow have shown an inverse
relationship with insulin and progesterone catabolic enzymes. In this study
growth hormone treatment resulted in increased peripheral concentrations of
insulin and progesterone, those ewes treated with growth hormone probably had
alterations in progesterone catabolism. Progesterone is converted into 21hydroxyporgesteron or 6ß-hydroxyprogesterone via hepatic cytochrome P450 2C
and 3A, respectively (Murray 1991, 1992). Smith et al., (2006) found that
anestrus ewes had decreased progesterone clearance when orally gavaged with
propionate, a gluconeogenic substrate that stimulates insulin secretion in
ruminants. Ewes supplemented with sodium propionate had elevated insulin
concentrations and a 45% reduction in hepatic cytochrome P450 2C and 3A
activity at 1 hour after feeding compared to an energy control group (Lemley et
al., 2008a). Progesterone catabolism may be altered acutely by a reduction in
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cytochrome P450 activity during hepatic exposure to elevated insulin
concentrations. Lemley et al., (2008b) found that dairy cows chronically exposed
to a hyperinsulinemic-euglycemic clamp had a dose-dependent descrease in
hepatic cytochrome P450 2C and 3A mRNA expression versus insulin dosage.
In the current experiment, no difference was observed in the total number
of blastomeres or the trophectoderm to inner cell mass ratio even though lambs
born to ewes treated with a periconceptional injection of GH are approximately
10% larger at birth (Costine et al., 2005). It may not be surprising that no
difference was found considering that progesterone treatment from days 1-3
advanced embryonic development as measured by the number of blastomeres
per embryo on day 3 (Kleemann et al., 1994). In a similar study in which
progesterone was administered from day 4-9 of gestation, no difference was
found in conceptus development on day 10 (Ashworth and Bazer, 1989).
Histotrophic nutrients bathe the embryo in the uterus and consist of
enzymes, growth factors, ions, cytokines, hormones, adhesion molecules and
transport proteins (Spencer and Bazer, 2004; Aguilar and Reyley, 2005;
Igwebuike, 2006). In this study, TGFß-1 was elevated in uterine flushings of
ewes treated with a periconceptional injection of GH. Previously, our laboratory
reported that periconceptional injection of GH increased IGF-I in a dose
dependent manner on day 7 (Costine et al., 2005). Growth factors play an
important role in embryonic and fetal growth and appear to be differentially
secreted into a uterine environment from the time an embryo is a single cell
through term (Watson et al., 1994). In particular, IGF-I is known to be the most
60

important fetal growth promoter and is correlated with birth weight and crownrump length (Bauer et al., 1998). Further investigation into other growth factors
that are secreted by the oviductal and uterine epithelium that are differentially
expressed in response to a periconceptional GH injection may provide additional
insight into what factors program embryonic cells leading to a more efficient
placenta and larger lambs at birth.
In the current experiment, the concentration of urea was decreased in
uterine flushing in those animals treated with a periconceptional injection of GH.
This finding may be a result of changes in amino acid metabolism. Growth
hormone can stimulate the accretion of protein which would lead to a reduction in
amino acid oxidation and overall less urea production. The increase in amino
acid utilization may be from an increase in uterine gland secretion or production
of other uterine proteins. While urea may not directly program the embryo, it may
be correlated with a reduction in the overall amino acids in circulation and in
uterine flushings. Unfortunately the methods used in this experiment to collect
embryos diluted uterine flushings by 20 ml and made it difficult to detect amino
acids.
In conclusion, periconceptional GH administration appears to alter some
aspects of uterine environment which may be mediated through an increase in
maternal progesterone, but further investigation into changes in uterine
environment following periconceptional GH treatment is required. The changes
that were observed did not appear to alter embryonic growth as determined by
total cell number or trophectoderm to inner cell mass ratio. Future studies should
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investigate the possible mechanisms in which programming of the embryo occurs
leading to an increased placental efficiency and larger lambs at birth as a result
of a single periconceptional growth hormone treatment.
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Abstract
Fetal growth is limited by the ability of the placenta to provide the proper
nutrients required for growth, including glucose, which is the primary source of
energy and amino acids which are required for protein accretion. These nutrients
move from maternal circulation to fetal circulation by a variety of nutrient
transporters. We have demonstrated that sustained release growth hormone
(GH) given to ewes at breeding increases placental efficiency and birth weight.
The objective of this experiment was to determine if GH at breeding alters the
expression of placental nutrient transporters, including glucose transporters
(GLUT)-1 and -3, as well as amino acid transporters EAAT-1, EAAT-3, LAT-1,
LAT-2, CAT-1 and SNAT-2. Ewes were mated at estrus and half of the ewes
were given 500 mg of sustained release GH at the time of breeding. On days 80
and 140 of gestation an umbilical blood sample and cotyledonary tissue were
collected. The RNA from cotyledonary tissue was extracted and used to
determine the expression of nutrient transporters by real-time RT-PCR.
Treatment with GH did not alter the expression of GLUT-1 or GLUT-3; however,
GLUT-3 expression increased from day 80 to 140 of gestation. There was a
treatment by day interaction for both EAAT-1 and EAAT-3. Expression in the
controls increased from day 80 to 140 of gestation, but those in the GH group
had similar expression on day 80 and 140 of gestation which was similar to
controls on day 140. Treatment did not alter the expression of LAT-2, CAT-1 and
SNAT-2, however, expression increased from day 80 to 140 of gestation. There
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was no effect of treatment or day on the expression of LAT-1. A positive
correlation was observed between fetal size as measured by fetal weight, with
GLUT-3, EAAT-3 and SNAT-2. A positive correlation was also observed
between crown-rump length, and EAAT-3 and LAT-1. The increase in live weight
observed in lambs born to ewes treated with GH at breeding may be a result of
increased uptake of amino acids transported by EAAT’s from maternal
circulation, which are essential for protein accretion. This may be one reason
why lambs born to ewes treated with growth hormone are larger at birth.
Key Words: Growth Hormone, Glucose Transporters, Amino Acid Transporters
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Introduction
Nutrients need to be delivered in sufficient supply to the developing fetus
in a timely fashion for proper growth and development. In the last third of
gestation, a period in which fetal growth increases exponentially, limiting fetal
nutrient availability has been directly linked to intrauterine growth restriction and
long term alterations in organ function. Until recently, investigators have
suggested that limiting nutrient availability was the cause of fetal growth
restriction; however, some have argued that if the number of transporters are
limited, no matter what the nutrient availability, intrauterine growth restriction
occurs (Jansson et al., 2006). Therefore, the efficiency of the placenta may play
a major role in the developmental potential of the fetus.
Nutrients, including glucose and amino acids, are shuttled from maternal
to fetal circulation by specific transporters. Both GLUT-1 and GLUT-3 are
present in placental tissue and expression increases for both transporters until
about mid gestation, but GLUT-3 expression continues to increase till term
(Currie et al., 1997; Ehrhardt and Bell, 1997). Several amino acid transporter
families have been identified in placental tissue; including those in the A, ASC,
B0, X-AG, b0,+, L and y+. These systems work together to transport amino acids
across epithelial layers of both the maternal and fetal placenta.
Previously, our laboratory demonstrated that growth hormone (GH)
administered at breeding alters both fetal and placental growth (Costine et al.,
2005). Lambs are at least 10% heavier at birth and the weight difference is
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maintained when reared as singles. The placental growth pattern in GH treated
ewes is dramatically altered in that placental growth does not plateau at
midgestation but instead growth is linear. As a result of this altered growth
pattern placentae of in the growth hormone group are more efficient (fetal weight/
chorioallantoic weight) compared to controls (Costine et al., 2005). Therefore the
objective of the current experiment was to determine if GH treatment at the time
of breeding alters the expression of nutrient transporters in cotyledonary tissue.

Materials and Methods
Ewes, of mixed breeding, from the West Virginia University farm were
used for the experiment. All procedures were approved by the West Virginia
University Animal Care and Use Committee (03-1012).
The cotyledonary tissue and fetal samples utilized in this experiment were
collected previously by Costine et al. (2005). Briefly, ewes were randomly
assigned to either a control group or a GH treated group. The GH treated group
received a single 500 mg injection of sustained release recombinant bovine GH
subcutaneously (Posilac; Monstanto, St. Louis, MO) at the time of mating. On
day 80 or 140 of gestation dams were euthanized with a lethal injection of
sodium pentobarbital (Sigma; St. Louis, MO) and the pregnant uterus was
removed. The fetuses were removed from the uterus and fetal body weight and
crown-rump length were determined (Costine et al., 2005). Cotyledons were
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physically removed from caruncular tissue. The cotyledonary tissue was snap
frozen and stored at -80°C until further analysis.
Real-Time RT PCR
Placental RNA was extracted using TRIzol as described by Koch et al.
(2007). This procedure includes two back extractions against acid
phenol:chloroform (5:1; pH=4.5; Ambion, Austin, TX) followed by two back
extractions against phenol:chloroform: isoamyl alcohol (25:24:1; pH=6.6) to
remove additional proteins, DNA and lipids. The RNA was reconstituted in 30 µl
of nuclease free water and the concentration was determined
spectrophotometrically at 260 nm. The quality of RNA was determined by the
appearance of bands corresponding to 28S and 18S rRNA and a distribution of
mRNA of high molecular weight on a 3% agarose gel with ethidium bromide.
Complementary DNA (cDNA) was synthesized from 2 µg of RNA which was
reverse transcribed using random hexamers and Moloney Murine Leukaemia
Virus reverse transcriptase (Promega, Madison, WI). Real-Time RT PCR
(iCycler, Bio-Rad Laboratories, Hercules, CA) was utilized to quantify the
abundance of cDNA as previously described (Koch et al., 2007). Primers
specific for all nutrient transporters and the control gene, acidic ribosomal
protein, (FOR: CAACCCAGCTCTGGAGAAAC; REV:
GTGAGGTCCTCCTTGGTGAA with 100% efficiency) were designed using
Biology Work Bench (http://workbench.sdsc.edu/) and synthesized (Table 4;
Integrated Diagnostics Systems, Coralville, IA). All primer sets were optimized
(all reactions were annealed at 58.7 °C) using a pooled RNA sample which was
created by combining RNA from both treatment groups. The efficiency (E) of
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Gene

System
Name

Substance
Transported

Primer Sequence

Efficiency

EAAT-1
(SLC1A3)

XAG-

Anionic Amino
Acids (GLU,
ASP)

FOR: TTTTTATCGGAGGGTTGCTG

82%

EAAT-3
(SLC1A1)

LAT-1
(SLC7A5)

LAT-2
(SLC7A8)

CAT-1
(SLC7A1)

XAG-

L

L

y+

REV: ATCTGGTAACGCGTTTGTCC

Anionic Amino
Acids (GLU,
ASP)

FOR: GGCTTACTCTCTGGTGGCTG

Neutral Amino
Acids (LEU,
ILE, VAL, TYR,
PHE, MET)

FOR: TACTTCCTTGGGGTCTGGTG

Neutral Amino
Acids (LEU,
ILE, VAL, TYR,
PHE, MET)

FOR: CACCAGCGACATATACACGC

Cationic Amino
Acids

FOR: TCAACCAGCCTCCTAGCACT

87%

REV: TGCTGCTCACCAACTCATTC
99%

REV: TCTGGTCGCTTACGTCTCCT
83%

REV: CTTAATGGGGCGATTGATGT
97%

REV: AGGCAGAGCCCATGAGTAGA
SNAT-2
(SLC38A2)

GLUT-1
(SLC2A1)

A

Neutral Amino
Acids (ALA,
SER, PRO,
GLN)
Glucose

FOR: AGTGCTCCATTGGGTGAAAC

95%

REV: CCGTCTTCTCACTGCCTTTC
FOR: AACTGTGCGGACCCTATGTC

102%

REV: GTCACTTTGGCTTGCTCCTC
GLUT-3
(SLC2A3)

Glucose

FOR: CTGAGATGGAGGGATTGCAT

91%

REV: TGAAGAGCCCAGTCTCCACT

TABLE 4. Nutrient transporter primer sequences and the efficiency for each
primer set.
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each primer set was determined utilizing this pool prior to assaying any samples,
and was used to standardize the target gene ratio. The efficiency of amplification
was determined by raising 10 to the power of (-1/slope), for which the slope was
obtained by plotting the log of the concentration of cDNA against the critical
threshold (Ct) values (Koch et al., 2007).
The PCR reaction contained 25 µl of iQ SYBR green supermix (Bio-Rad
Laboratories), 2 µl of cDNA diluted to 1:2, and 3 µl each of 5 µM forward and
reverse primer and 17 µl of water to reach a final reaction volume of 50 µl for
GLUT-1, GLUT-2, LAT-2, EAAT-1 and EAAT-3 or 3 µl of cDNA diluted 1:2 and 3
µl each of 5 µM forward and reverse primer and 16 µl of water to reach a final
reaction volume of 50 µl for CAT-1, SNAT-2 and LAT-1. A single product per
amplification was determined by examining both the melting curve and by a 1.5%
agarose gel with ethidium bromide. The expression of each gene is reported as
a ratio (ratio = [E∆Ct target gene (pool-sample)/ E∆Ct control gene (pool-sample)]) which was
previously described by Koch et al. (2007).

Statistical Analysis
The main effect of growth hormone treatment, day and the treatment by
day interaction on the cotyledonary expression of GLUT-1, GLUT-3, EAAT-1,
EAAT-3, LAT-1, LAT-2, CAT-1, SNAT-2 was analyzed by analysis of variance,
utilizing the general linear models procedure in SAS. The correlation between
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nutrient transporters, body weight and crown-rump length of the fetus were
determined using the correlation procedures of SAS.

Results
Periconceptional treatment of ewes with GH did not alter the expression of
either GLUT-1 or GLUT-3 (0.52 ± 0.08; 0.78 ± 0.11) in the placenta. However,
expression of GLUT-3 was greater (p < 0.05) on day 140 compared to day 80
(Figure 7).
Periconceptional treatment of ewes with GH altered the expression of
EAAT-1 and EAAT-3. The expression of EAAT-1 increased (p < 0.05) in the
control group from day 80 to 140 of gestation. However, the GH treated group
had similar expression on day 80 and 140 of gestation, which was similar to the
expression of the control group on day 140 (Figure 8). A similar pattern of
expression was observed for EAAT-3 in that expression in the control group was
greater (p < 0.05) on day 140 than day 80. However, the GH group had an
elevated expression on day 80 compared to the controls and maintained the
same level of expression on day 140 (Figure 9).
Expression of the other amino acid transporters that were studied
including CAT-1, SNAT-2 and LAT-2 were not affected by GH treatment, but had
an increase (p < 0.05) in expression from day 80 to day 140 (Figure 10, 11, and
12). The expression of LAT-1 was not affected by treatment or day (1.18 ± 0.09).
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A positive correlation between fetal weight and GLUT-3 (r = 0.49, p <
0.05), EAAT-3 (r = 0.49, p < 0.05) and SNAT-2 (r = 0.41, p < 0.05) was observed.
Similarly a positive correlation was detected between crown-rump length and
EAAT-3 (r = 0.35, p < 0.05) and LAT-1 (r = 0.38, p < 0.05).
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1.4

*

Target Gene Ratio

1.2

1.0

0.8

0.6

0.4

0.2

Day 80

Day 140

FIGURE 8. The expression of GLUT-3 in cotyledonary tissue collected on day 80
and 140 of gestation. * Indicates a difference between days (p < 0.05).
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Target Gene Ratio
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1.0
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0.6

a

0.4

Day 80

Day 140

Figure 9. Expression of EAAT-1 in cotyledonary tissue collected on day 80 and
140 of gestation from conceptuses gestated by control ewes or ewes treated with
sustained release growth hormone at breeding. Means with different letters differ
(p < 0.05).
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Target Gene Ratio
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b
0.8

0.6

0.4

a

0.2
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Day 140

Figure 10. Expression of EAAT-3 in cotyledonary tissue collected on day 80 and
140 of gestation from conceptuses gestated by control ewes or ewes treated with
sustained release growth hormone at breeding. Means with different letters differ
(p < 0.05).
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Target Gene Ratio
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1.2

1.0

0.8

0.6

Day 80

Day 140

Figure 11. The expression of CAT-1 in cotyledonary tissue collected on day 80
and 140 of gestation. * Indicates a difference between days (p < 0.05).
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1.2
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0.8
0.6

Day 80

Day 140

Figure 12. The expression of SNAT-2 in cotyledonary tissue collected on day 80
and 140 of gestation. * Indicates a difference between days (p < .05).
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Day 140

Figure 13. The expression of LAT-2 in cotyledonary tissue collected on day 80
and 140 of gestation. * Indicates a difference between days (p < 0.05).
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Discussion
Cotyledonary expression of GLUT-3 increased from day 80 to 140 of
gestation and was positively correlated with fetal weight. However, no difference
in the expression of GLUT-1 was observed in this experiment. Glucose is
essential to the fetus because it is the primary substrate for fetal energy and
metabolism and is passively transferred from maternal circulation to the fetal
circulation by a concentration-dependent mechanism via sodium independent
transporters GLUT-1 and GLUT-3 (Robertson and Karp, 1976; Jansson et al.,
1993; Bell et al. 1999; Limesand et al., 2004; Wooding et al., 2005).
The increase in GLUT-3 mRNA expression with an increase in gestational
age observed in this experiment is similar to previous data in which total
placental mRNA expression continued to increase as the day of gestation
increased (Currie et al., 1997; Ehrhardt and Bell, 1997). The expression of
GLUT-1 in this experiment is similar to the expression data observed by Currie
and coworkers (1997) in which GLUT-1 expression did not increase between day
60 and 140 of gestation. However, Ehrhardt and Bell (1997) using twin
pregnancy and northern blotting, reported an increase in GLUT-1 expression
from day 75 to 140. The magnitude of change in GLUT-1 expression observed
by Ehrhardt and Bell (1997) was relatively small (1.8 times), compared to the
change in GLUT-3 expression (3.9 times). Data available on for GLUT-1
expression is not consistent and may vary because of fetal number or the
methodology used to determine expression.
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The majority of information available on amino acid transporters in the
placenta comes from human studies and has been reviewed in great detail
(Roberston et al., 1976; McGivan and Pastor-Anglada, 1994; Jansson, 2001;
Kudo and Boyd, 2001; Regnault). However, what information is available on
amino acid transport in the sheep is limited to uptake of nonmetabolizable amino
acids, or amino acid flux into fetal circulation, from chronically instrumented
fetuses, and not on transporter expression or location (Lemons et al., 1976;
Jozwik et al., 2004; Vrijer Kwon et al., 2004; et al., 2004).
Nutrients have to be in sufficient supply and delivered to the developing
fetus in a timely fashion for proper growth and development. In the last third of
gestation, a period in which fetal growth increases exponentially limiting fetal
nutrient availability, has been directly linked to intrauterine growth restriction and
long term alterations in organ function. The mechanisms by which this occurs
includes a decrease in maternally derived nutrients or insufficient transport of
nutrients across the placenta (Barker 1995; Ravelli et al. 1999; Godfrey & Barker
2000; Jensen et al. 2002; Armitage et al. 2004; Wu et al. 2004; Wallace et al.
2005; Wu et al. 2006). Until recently, investigators have suggested that limiting
nutrient availability was the cause of fetal growth restriction; however, recent
evidence suggests that if the number of transporters is limited, no matter what
the nutrient availability is, intrauterine growth restriction occurs (Jansson et al.,
2006).
Cotyledonary expression for both EAAT-1 and EAAT-3 was affected by
treatment and day. The expression for both EAAT-1 and EAAT-3 increased from
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day 80 to 140 of gestation in the control group. However, GH treatment led to an
increased expression of both transporters on day 80 of gestation, which was
similar to the expression observed on day 140. The elevated expression
observed on day 80 of gestation in the growth hormone group may be just one
reason why lambs are larger at birth. This information further supports the
concept that growth hormone alters placental efficiency. As previously reported,
placental efficiency as measured by fetal weight divided by chorioallantoic weight
is greater on day 80 of gestation in ewes that were treated with growth hormone
at breeding (Costine et al., 2005). The increase in EAAT-1 and EAAT-3 on day
80, which is similar the level of expression on day 140 in the controls, may be
just one mechanism by which these placentas are capable of transporting more
nutrients compared to control placenta and therefore more efficient.
Cotyledonary expression of CAT-1, SNAT-2, LAT-1 and LAT-2 were not
altered by growth hormone treatment at breeding. However, expression of all of
the transporters, except LAT-1, increased from day 80 to 140 of gestation. This
observation is not surprising in that as fetal growth rate increases the amount of
nutrients required to support growth increases as well. Therefore, an increase in
transporter number may occur just to meet fetal nutrient demands.
In conclusion, growth hormone treatment at breeding increases
cotyledonary expression of EAAT-1 and EAAT-3 in the sheep at midgestation,
which is maintained throughout the rest of gestation. While this is only one
transporter, it may give further insight into a possible mechanism by which
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growth hormone treatment to the ewe at breeding leads to a more efficient
placenta during gestation and therefore, larger lambs at birth.
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Abstract
Altering the fetal environment can modify the composition or growth rate of
the fetus, a concept known as fetal programming. A majority of the research in
this area has focused on intrauterine growth restriction (IUGR), which has been
linked to adult diseases. A few studies have attempted to ameliorate the
negative effects of IUGR, by applying growth promoters late in gestation. The
objective of this study was to determine the effects of a single treatment of
sustained release growth hormone given during the periconceptional period on
fetal growth and development. Ewes assigned to treatment received 500 mg of
sustained release growth hormone. Birth weight, crown-rump length and
abdominal girth were determined and a serum sample collected to determine
IGF-I concentrations in all lambs. In a subset of male lambs, liver, heart and
brain weights, as well as left and right ventricular wall thickness and liver IGF-I
and growth hormone receptor mRNA expression were determined. On postnatal
day 100 a subset of ewe lambs were weighed and challenged with growth
hormone releasing hormone to assess the functionality of the growth hormone
axis. Lambs from treated ewes had increased birth weight and abdominal girth
compared to control lambs; however, there was no difference in crown-rump
length. Hepatic mRNA expression of growth hormone receptor was increased,
and IGF-I tended to increase, in lambs gestated by growth hormone treated ewes
compared to controls. The left ventricular wall was thinner from lambs in the
growth hormone treated group compared to controls. On postnatal day 100,
those ewe lambs born to ewes treated with growth hormone were heavier and
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had a reduced IGF-I response to growth hormone releasing hormone challenge.
In conclusion, treating ewes with sustained release growth hormone not only
increased lamb birth weight but also resulted in alteration in lamb growth and
altered growth hormone axis.
Key Words: growth hormone, fetal growth, GHRH challenge
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Introduction
The concept of “fetal programming” is described as any stimulus, either
positive or negative, that occurs in utero which has a permanent affect and alters
the physiology of the offspring (Armitage et al., 2004). The list of systems in
which fetal programming has been found to impact is lengthy and includes the
cardiovascular, respiratory, endocrine, reproductive, central nervous, skeletal
and immune systems as well as kidney and liver function (Godfrey & Barker
2000; Wu et al., 2004). The observation that adult onset diseases are directly
linked to fetal programming has brought about investigations of a number of
animal models in an attempt to mimic the pathophysiology observed in humans
(Wallace et al., 2005; Wu et al., 2006).
Models developed to date to investigate fetal programming exclusively
induce intrauterine growth restriction (IUGR). Intrauterine growth restriction is an
alteration in the uterine environment at any time point during gestation that is
detrimental to the growth and development of the fetus. The methods for
inducing IUGR can involve maternal dietary manipulation and/or induction of
placental insufficiency (Armitage et al., 2004; Wu et al., 2006). Maternal dietary
manipulation includes a range of approaches from nutrient restriction to
overnourishing adolescent ewes. Both models result in decreased nutrient
availability to the developing fetus, but the overnourished adolescent ewe model
appears to induce IUGR by reducing placental efficiency (Armitage et al., 2004;
Wallace et al., 2005; Wu et al., 2006). In addition to the overnourished
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adolescent ewe, other placental insufficiency models alter the placenta’s ability to
transport nutrients to the fetus and include, uterine artery ligation, placental
embolism, carunclectomy and maternal hyperthermia (Bell et al., 1989; Thureen
et al., 1992; Regnault et al., 2003; Amitage et al., 2004; Wallace et al., 2004;
Louey et al., 2005).
Many models that lead to IUGR have been studied in detail, and the
specific alterations in fetal physiology that result from the environmental insult are
well documented. However, only a few studies have tried to ameliorate the
impact of experimentally induced IUGR by administering growth promoters. The
limited number of studies that have attempted to attenuate the negative impact
on fetal physiology have examined growth hormone treatment to the dam or
infusing the fetus directly with growth hormone or insulin like growth factor (IGF;
Harding et al., 1997; Bauer et al., 2003; Wallace et al., 2004; Wallace et al.,
2006). In these studies the effects of growth hormone, given during either mid or
late gestation, only appear to have a transient effect (i.e., they were not able to
overcome the negative impact IUGR had on growth and development of the
offspring).
Few researchers have attempted to promote fetal growth and
development under normal uterine conditions. Growth hormone administered to
either the fetus or the dam, late in gestation under normal gestational conditions,
did not alter fetal growth and development (Stelwagen et al., 1994; Bauer et al.,
2000). However, these experiments may have two potential flaws. First growth
hormone is not the primary stimulator for growth during fetal development
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because hepatic growth hormone receptors are in very low abundance and do
not appear to stimulate the secretion of IGF, which is the primary growth
promoter (Gluckman and Pinal, 2003). Second, growth hormone was
administered following the majority of placental growth and altering placental
development may limit fetal growth because it regulates the nutrient supply. In
sheep, placental size increases exponentially until day 80, and from that point,
further development is mainly due to increased vascular complexity (Reynolds et
al., 2005a; Reynolds et al., 2005b; Borowicz et al., 2007). Recently we have
shown that a single injection of sustained release growth hormone administered
at breeding altered the uterine environment at day seven of gestation and
increased birth weight by 10% (Costine et al., 2005). At day 80 of gestation,
placental mass in the growth hormone group was lower than controls, but by day
140 both had similar placental weights (Costine et al., 2005). Comparing the
results of experiments in which growth hormone was administrated in mid or late
gestation with that at the time of breeding has led us to suggest that early growth
hormone administration alters the uterine environment during a developmental
window in which the embryo, including the trophectoderm (which will become the
outer layer of the fetal placenta), and in inner cell mass (which will become the
embryo proper and later fetus and contribute to the placenta) can be altered.
Therefore, the objective of the current study was to determine how a
single injection of sustained release growth hormone, given immediately prior to
conception, alters: 1) fetal growth and development 2) postnatal growth and
development of the growth hormone axis.
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Materials and Methods
Ewes (n=50), primarily of rambouillet breeding, from the West Virginia
University farm were used for the experiment. All procedures were approved by
the West Virginia University Animal Care and Use Committee (ACUC No. 031012).
Estrus was synchronized by administering 20 mg of prostaglandin F2α
(Lutalyse, Pfizer) on day 0 and a second injection of prostaglandin F2α on day 8.
Ewes were randomly assigned to either a control group (n=27) or a growth
hormone treated group (n=23). The growth hormone treated group received a
single 500 mg injection of sustained release recombinant bovine growth hormone
subcutaneously (Posilac; Monstanto, St. Louis, MO) at the same time as the
second prostaglandin F2α injection. This dose was previously reported to
increase uterine luminal insulin like growth factor-I (IGF-I) on day 7 of gestation
and result in larger lambs at birth (Costine et al., 2005). Following the second
injection of prostaglandin F2α, ewes were penned with a fertile ram. At term, all
lambs (n=84) born alive were processed shortly after birth (average gestation
was 145 days).

Lamb Data
Shortly following birth, and before nursing, all lambs were processed.
Each lamb was weighed, measured for crown-rump length, abdominal girth and
crown width and a blood sample was collected for IGF-I concentration. A subset
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of males (n=22) were further processed for tissue collection. Each male was
euthanized with an intravenous overdose of sodium pentobarbital (1.5g, Sigma,
St. Louis, MO). The liver was removed, weighed and a portion was snap frozen
in liquid nitrogen for further analysis of hepatic expression of growth hormone
receptor and IGF-I. The heart was removed and weighed before the ventricles
were separated from the atria and fixed in 10% formalin. Following fixation the
right and left ventricular wall thickness was determined using calipers. The brain
was also removed from the skull to determine brain weight.

Growth Hormone Releasing Hormone Challenge
A subset of ewe lambs (n=14) were weighed at 100 days-of-age and a
blood sample was collected (0 min). The lambs were then subjected to a growth
hormone releasing hormone challenge (3 µg/kg body weight; GHRH factor-29;
Simga, St. Louis, MO; Suttie et al., 1991) and blood samples were collected 10,
20, 30, 45, 60 and 90 min following challenge.

Insulin Like Growth Factor-I
The concentration of IGF-I in plasma was determined using a
commercially available Enzyme-Linked ImmunoSorbent Assay, previously
validated in our laboratory (Diagnostic Systems Laboratories Inc., Webster, TX;
Costine et al.,, 2005). Briefly, this assay utilizes two antibodies in a sandwichtype immunoassay. The enzyme horseradish peroxidase is linked to the
secondary antibody and in the presence of tetramethylbenzidine, a substrate for
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horseradish peroxidase, the absorbance is directly proportional to the
concentration of IGF-I.

Gene Expression
Liver RNA was extracted using TRIzol as described by Koch et al. (2007).
This procedure includes two back extractions against acid phenol:chloroform
(5:1; pH=4.5; Ambion, Austin, TX) followed by two back extractions against
phenol:chloroform: isoamyl alcohol (25:24:1; pH=6.6) to remove additional
proteins, DNA and lipids. The RNA was reconstituted in 40 µl of nuclease free
water and the concentration was determined spectrophotometrically at 260 nm.
The quality of RNA was determined by the appearance of bands corresponding
to 28S and 18S rRNA and a distribution of mRNA of high molecular weight on a
3% agarose gel with ethidium bromide. Complementary DNA (cDNA) was
synthesized from 2 µg of RNA which was reverse transcribed using random
hexamers and Moloney Murine Leukaemia Virus reverse transcriptase
(Promega, Madison, WI). Real-Time RT PCR (iCycler, Bio-Rad Laboratories,
Hercules, CA) was utilized to quantify the abundance of cDNA as previously
described (Koch et al., 2007). Primers specific for growth hormone receptor,
IGF-I and acidic ribosomal protein (which was used as a control gene), were
designed using Biology Work Bench (http://workbench.sdsc.edu/) and
synthesized (Integrated Diagnostics Systems, Coralville, IA). Primers for growth
hormone receptor (forward CATGTCACTGGACAGATGGG; reverse
TGTTTTCACCAGCAGAGACG), IGF-I (forward GCCAAAACGGTCAAAGGTGA;
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reverse AGGCATAATTGGGGAGCTTT) and acid ribosomal protein (forward
CAACCCAGCTCTGGAGAAAC; reverse GTGAGGTCCTCCTTGGTGAA) were
optimized (all reactions were annealed at 58.7 °C) using a pooled RNA sample
which was created by combining RNA from both treatment groups. The
efficiency (E) of each primer set was determined utilizing this pool prior to
assaying any samples, and was used to standardize the target gene ratio. The
efficiency of amplification was determined by raising 10 to the power of (1/slope), for which the slope was obtained by plotting the log of the concentration
of cDNA against the critical threshold (Ct) values (Koch et al., 2007). Efficiencies
for growth hormone receptor, IGF-I and acid ribosomal protein were 1.84, 1.85
and 1.94, (i.e., 92%, 93% and 97% theoretical yield) respectively.
Each PCR reaction contained 25 µl of iQ SYBR green supermix (Bio-Rad
Laboratories), 2 µl of cDNA diluted to 1:2, and 3 µl each of 5 µM forward and
reverse primer and 17 µl of water to reach a final reaction volume of 50 µl. A
single product per amplification was determined by examining both the melting
curve and by a 1.5% agarose gel with ethidium bromide. The expression of each
gene is reported as a ratio (ratio = [E∆Ct target gene (pool-sample)/ E∆Ct control gene (poolsample)

]) previously described by Koch et al. (2007).

Statistical Analysis
The effect of growth hormone treatment to the dam during the
periconceptional period on lamb birth weight, crown-rump length, abdominal
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girth, crown width, IGF-I concentration, brain weight, right and left ventricular wall
thickness and hepatic expression of IGF-I and growth hormone receptor was
analyzed by analysis of variance, utilizing the general linear models procedure in
SAS. The effect of GH treatment to the dam on IGF-I concentrations following
GHRH challenge was analyzed by repeated measures ANOVA utilizing the
mixed models procedure in SAS. The relationships among variables were
determined by the correlation procedure of SAS. Insulin like growth factor-I
concentrations following growth hormone releasing hormone challenge were
analyzed by repeated measures ANOVA.

Results
Both weight and abdominal girth at birth were greater (P < 0.05) in the
group of lambs born to ewes treated with growth hormone compared to those
born to control ewes (Figure 13a and 13b). However, no difference in crownrump length (48.51 ± 1.44 cm; P > 0.05; Figure 13c) or crown width (8.82 ± 0.20
cm) was detected.
The thickness of the left ventricular wall at birth was decreased (P < 0.05)
in male lambs born to ewes treated with growth hormone compared to male
lambs born to control ewes (Figure 14). However, no difference in the thickness
of the right ventricular wall was detected (Figure 14). No difference in heart
weight at birth was detected between the control and growth hormone groups
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(34.7 ± 2.1 g; p > 0.05). Brain weights were also not different (50.4 ± 2.1 g; p >
0.05).
Relative expression of growth hormone receptor was increased (p < 0.05)
in liver tissue of male lambs born to ewes treated with growth hormone compared
to control (Figure 15). Similarly, there was a trend (p = 0.06) for an increase in
IGF-I expression in the growth hormone group compared to controls (Figure 15).
However, liver weight at birth was not different between control male lambs and
male lambs born to ewes treated with growth hormone at breeding (108.9 ± 5.1
g; p > 0.05). Plasma IGF-I at birth was not different in lambs from either
treatment group (38 ± 6.6 pM). However, there was a positive correlation
(r=0.48; p < 0.05) between birth weight and IGF-I concentration.
On postnatal day 100, ewe lambs born to ewes treated with growth
hormone where still 20% heavier than those born to control ewes (Figure 16).
Ewe lambs born to dams treated with growth hormone had a reduced IGF-I
response following the growth hormone releasing hormone challenge on day 100
(Figure 17).
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FIGURE 14. Birth data of lambs born to control ewes and ewes treated with
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Discussion
Administering a single injection of sustained release growth hormone prior
to breeding alters fetal growth and development of lambs. Lambs born to ewes
treated with growth hormone at breeding are 25% heavier at birth compared to
controls. Lambs in the growth hormone group appear to have an altered
composition, as indicated by the observed increased abdominal circumference
without a difference in crown-rump length, leading us to suggest that the stature
of the growth hormone group is unaltered.
The increase in birth weight of lambs born to ewes treated with growth
hormone in the current experiment is in agreement with those found previously in
which 500 mg of sustained release growth hormone given at the time of breeding
increased lamb weight by 10% (Costine et al., 2005), even though in the current
experiment growth hormone was given at the time of the second prostaglandin
F2α injection. In contrast, administration of 0.1 mg/kg growth hormone twice daily
to the dam for 10 days or once daily for 27 day in late gestation did not affect
fetal growth (Stelwagen et al., 1994; Harding et al., 1997).
Several researchers have attempted to ameliorate the effects of
intrauterine growth restriction by administering growth hormone during the latter
portion of fetal development, but to our knowledge only Costine et al. (2005; from
this laboratory) and the current experiment have administered growth hormone
during the periconceptional period or in early gestation. For example, in an
experiment conducted by Bauer et al. (2003) intrauterine growth restriction was
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induced by placental embolization on days 110-116 which was followed by direct
infusion of growth hormone to the fetus at a rate of 3.5 mg/day late in gestation.
Growth hormone infusion did not alter fetal weight, crown-rump length, chest
girth or fetal growth rate (Bauer et al., 2003). Wallace et al. (2004) utilized the
over-nourished pregnant adolescent ewe model as a means to induce fetal
growth restriction and examined whether 0.14 mg/kg growth hormone
administered daily to the dam in mid gestation (i.e., days 35-80) might alter fetal
development. In their study, growth hormone treatment appeared to have no
affect on either fetal weight or umbilical girth (Wallace et al., 2004). Utilizing the
same adolescent ewe model, growth hormone was administered late in gestation
to the dam at a rate of 0.14 mg/kg/day from days 95-125. At day 130, growth
hormone treatment appeared to increase fetal weight and girth in the growth
restricted group making them equivalent to non-growth restricted. However, at
birth the effect of growth hormone treatment was no longer observed, leading to
the suggestion that late in gestation growth hormone treatment only elicits a
transient response (Wallace et al., 2006).
It is not surprising that administration of growth hormone during mid or late
gestation does not increase fetal growth rate or ameliorate the effects of
intrauterine growth restriction. This is because fetal growth is generally limited by
the ability of the placenta to supply nutrients. The placenta grows in size during
the first 80 days of gestation and then for the remainder of gestation it develops a
larger, more complex vascular network to allow for the increased nutrient
demand of the rapidly growing fetus (Reynolds et al., 200a; Reynolds et al.,

106

200b; Borowicz et al., 2007). Apparently, growth hormone administration in mid
to late gestation only temporarily influences placental efficiency.
During fetal development, the impact of growth hormone is very minimal
even though the concentration of growth hormone is 10- to 20-fold higher than
postnatal levels (Bloomfield et al., 2006). Growth hormone’s inability to stimulate
fetal growth has been associated with a lack of growth hormone receptor
expression. Growth hormone receptor expression is low during fetal
development, but is induced by the glucocorticoid surge at parturition and
remains elevated in lambs (Li et al., 1996; Gluckman & Pinal 2003; Bloomfield et
al., 2006). The apparent failure of GH to ameliorate growth restriction should not
be expected since GH is not the main regulator of fetal growth.
Administration of growth hormone during mid gestation to adolescent
pregnant sheep more than doubled the concentration of glucose in fetal
circulation, although expression of both glucose transporters found in the
placenta were not altered (Wallace et al., 2004). In the uteroplacental embolism
model, growth hormone administration restored the glucose concentration of the
intrauterine growth restricted group to control concentrations (Bauer et al., 2003).
In the current experiment, growth hormone administration occurred
immediately prior to breeding. We have speculated that the observed increase in
fetal weight and abdominal girth in the current study are a result of altered
embryo growth that leads to altered placental development and function allowing
for an increased placental efficiency late in gestation. This early embryonic
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programming may be a result of an altered uterine environment which has been
observed with growth hormone treatment at breeding (Costine et al., 2005).
Exogenous progesterone administered during embryonic development appears
to advance the uterine environment and increase fetal growth. Those embryos
exposed to an altered uterine environment by early progesterone administration
had a greater fetal mass and larger crown-rump length compared to controls
(Keelmann et al., 1994). Similarly embryos that are co-cultured with granulosa
cells before being returned to the recipient female were 14% heavier by day 61 of
gestation and 18% larger by day 125 compared to those that were just cultured in
media and not exposed to granulosa cells (Sinclair et al., 1999).
As in the neonate, IGF-I is the major growth factor responsible for fetal
growth, but the main stimulator for IGF-I secretion in utero is nutrients, not growth
hormone (Oliver et al., 1996; Bloomfield et al., 2006). The postnatal drop in
growth hormone concentration, to that of an adult, is accompanied by an
increase in both the expression of growth hormone receptor and IGF-I, which
together lead to growth hormone regulated IGF-I secretion after birth (Fowden,
1995; Breier et al., 1994).
A positive correlation between placental efficiency and fetal IGF-I
concentrations has previously been observed in ewes treated with sustained
release growth hormone at breeding (Costine et al., 2005). The current study
found that treatment with growth hormone prior to breeding tended to increase
the hepatic mRNA expression of both IGF-I and growth hormone receptor at
birth. The major fetal growth promoter, IGF-I, is mainly regulated by nutrients
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(Bloomfield et al., 2006). Fetal expression of IGF-I and growth hormone receptor
can be influenced by maternal nutrition as well. A 60% maternal nutrient
restriction from day 28 to 80 followed by re-feeding to a control level until day 140
resulted in a decrease in fetal-hepatic IGF-I and growth hormone receptor at day
80 of gestation. However, in the nutrient restriction growth that was returned to a
control diet fetal-hepatic expression of both IGF-I and growth hormone receptor
were increased by day 140 suggesting regulation by nutrient availability (Brameld
et al., 2000).
Treatment with growth hormone prior to breeding also appeared to alter
the postnatal growth and development of lambs. At day 100 following birth lambs
born to ewes treated with growth hormone were still 20% heavier than lambs
born to controls. Ewe lambs born to growth hormone treated ewes also had a
suppressed response to growth hormone releasing hormone challenge
compared to controls.
Little information has been collected on the effects of growth hormone
administration during gestation on postnatal development in lambs and more
specifically how the growth hormone axis of these lambs may be altered. In the
current experiment plasma IGF-I levels immediately following birth were not
different between the treated and control groups. These results are similar to
those found by Stelwagen et al., (1994), in which the concentration of IGF-I
immediately following birth was not different between control lambs and those
exposed for 27 days to growth hormone late in gestation at a concentration of 0.1
mg/kg ewe body weight. In an IUGR environment induced by placental
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embolization, growth hormone treatment was able to elevate the concentration of
IGF-I in fetal circulation of the IUGR fetuses but only to control levels (Bauer et
al., 2003). These data agree with hepatic expression data, in which growth
hormone treatment late in gestation increased hepatic growth hormone receptor
expression, but not IGF-I (Bloomfield et al., 2006). The current experiment only
examined hepatic expression in newborn lambs and cannot be directly compared
to Bloomfield et al., (2006); however, it may be important to note that the
observed increase in hepatic mRNA expression of growth hormone receptor and
the trend of an increased IGF-I expression in the growth hormone group may
indicate an altered growth hormone axis.
The current study also determined ventricular wall thickness because
during fetal development, the heart can undergo adaptive changes to
compensate for alterations in fetal physiology. The observed decrease in left
ventricular wall thickness leads us to suggest that during fetal development those
offspring gestated by dams treated with growth hormone at breeding have
reduced peripheral vascular resistance. In sheep, under normal uterine
conditions, cardiomyocyte growth is primarily hyperplastic until terminal
differentiation, with the majority of hypertrophic growth occurring only after birth
(Burrell et al., 2003). This pattern of development is changed in models of
intrauterine growth restriction. For example, when placental embolization was
utilized to induce fetal growth restriction late in gestation, an increase in heart
weight, ventricular wall thickness and the right ventricular cardiomyocyte proteinto-DNA ratio (i.e., cell size) was observed in growth restricted fetuses compared
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to controls at day 130 (Murotsuki et al., 1997). Utilizing the same model, growth
restriction reduced relative heart weight (when corrected to fetal weight) and
retarded growth of the left ventricle as measured by a decreased proportion of
binucleated cardiomyocytes (i.e., inhibited maturation) at day 130 of gestation
(Bubb et al., 2007). A different intrauterine growth restriction model, in which
dams were nutritionally restricted to 50% of the control group from day 28 to day
78 of gestation, resulted in an increase in ventricular weight per gram of fetal
body weight (Vonnahme et al., 2003). A hypertrophic increase in the fetal
ventricular wall has been suggested to result from an increase in ventricular
afterload which is indicative of an increase in mean arterial pressure (Samson et
al., 2000; Vonnahme et al., 2003). A mechanism in which placental vascular
resistance may be increased in intrauterine growth restriction resulting in altered
fetal heart development has been postulated by Vonnahme et al. (2003). We
suggest that the reduced left ventricular wall thickness observed in the current
study is consistent with a decrease in mean arterial pressure in fetuses gestated
in ewes treated with growth hormone prior to breeding.
In conclusion, treating ewes with a single injection of sustained release
growth hormone prior to breeding alters fetal growth and development. Lambs
born to ewes treated with growth hormone are larger, they have a reduced
ventricular wall thickness (which is indicative of a reduced mean arterial
pressure) and they have what appear to be alterations in the growth hormone
axis. Impacting or programming the early embryo, specifically the developing
placenta, potentially alters fetal development throughout gestation. The placenta
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is responsible for supplying nutrients for proper growth, it influences mean
arterial pressure which impacts cardiovascular development, and its efficiency
may directly impact the growth hormone axis. The current work may stimulate a
new line of thinking when examining developmental programming of the
conceptus and how it ultimately alters postnatal growth and development of the
offspring.

112

References
Armitage, JA, YK Imran, PD Taylor, PW Nathanielsz, L Poston. 2004.
Developmental programming of the metabolic syndrome by maternal
nutritional imbalance: how strong is the evidence from experimental
models in mammals. Journal of Physiology. 561:355-377.
Bauer, MK, BB Breier, FH Bloomfield, EC Jensen, PD Gluckman, JE Harding.
2003. Chronic pulsatile infusion of growth hormone to growth-restricted
fetal sheep increases circulating foetal insulin-like growth factor-I levels
but not foetal growth. Journal of Endocrinology. 177:83-92.
Bauer, MK, JE Harding, BH Breier, PD Gluckman. 2000. Exogenous GH infusion
to late-gestational foetal sheep does not alter foetal growth and
metabolism. Journal of Endocrinology. 166:591-597.
Bell, AW, BW McBride, R Slepetis, RJ Early, WB Currie. 1989. Chronic heat
stress and prenatal development in sheep: I. Conceptus growth and
maternal plasma hormones and metabolites. Journal of Animal Science.
67:3289-3299.
Bloomfield, FH, PL van Zijl, MK Bauer, HH Phua, JE Harding. 2006. Effect of
pulsatile growth hormone administration to the growth-restricted fetal
sheep on somatotrophic axis gene expression in fetal and placental
tissues. American Journal of Physiology. 291:E333-E339.
Borowicz, PP, DR Arnold, ML Johnson, AT Grazul-Bilska, DA Redmer, LP
Reynolds. 2007. Placental growth throughout the last two thirds of
pregnancy in sheep: vascular development and angiogenic factor
expression. Biology of Reproduction. 76:259-267.
Brameld, JM, A Mostyn, J Dandrea, TJ Stephenson, JM Dawson, PJ Buttery, ME
Symonds. 2000. Maternal nutrition alters the expression of insulin-like
growth factors in fetal sheep liver and skeletal muscle. Journal of
Endocrinology. 167:429-437.
Breier, BH, GR Ambler, H Sauerwein, A Surus, PD Gluckman. 1994. The
induction of hepatic somatotrophic receptors after birth in sheep is
dependent on parturition-associated mechanisms. Journal of
Endocrinology. 141:101-108.
Bubb, KJ, ML Cock, MJ Black, M Dodic, WM Boon, HC Parkington, R Harding, M
Tare. 2007. Intrauterine growth restriction delays cardiomyocyte
maturation and alters coronary artery function in the fetal sheep. Journal
of Physiology. 578:871-881.

113

Burrell, JH, AM Boyn, V Kumarsamy, A Hsieh, SI Head, ER Lumbers. 2003.
Growth and maturation of cardiac myocytes in fetal sheep in the second
half of gestation. Anatomical Research. 274A:952-961.
Costine, BA, EK Inskeep, ME Wilson. 2005. Growth hormone at breeding
modifies concetpus development and postnatal growth in sheep. Journal
of Animal Science. 83:810-815.
Fowden, A. 1995. Endocrine regulation of foetal growth. Reproduction Fertility
and Development. 7:351-363.
Gluckman, PD, GS Pinal. 2003. Regulation of fetal growth by the somatotrophic
axis. Journal of Nutrition. 133:1741S-1746S.
Godfery, KM, DJP Barker. 2000. Fetal nutrition and adult disease. American
Journal of Clinical Nutrition. 71:1344S-1352S.
Harding, JE, PC Evans, PD Gluckman. 1997. Maternal growth hormone
treatment increases placental diffusion capacity but not fetal or placental
growth in sheep. Endocrinology. 138:5352-5358.
Kleemann, DO, SK Walker, RF Seamark. 1994. Enhanced fetal growth in sheep
administered progesterone during the first three days of pregnancy.
Journal of Reproduction and Fertility. 102:411-417.
Koch, JM, JS Moritz, DC Lay Jr, ME Wilson. 2007. Effect of melengestrol acetate
as an alternative to induce molting in hens on the expression of yolk
proteins and turnover of oviductal epithelium. Animal Reproduction
Science. 102:14-23.
Lang, U, RS Baker, J Khoury, KE Clark. 2000. Effects of chronic reduction in
uterine blood flow on fetal and placental growth in the sheep. American
Journal of Physiology. 279:R53-R59.
Li, J, JA Owens, PC Owens, JC Saunders, AL Fowden, RS Gilmour. 1996. The
ontogeny of hepatic growth hormone receptor and insulin-like growth
factor I gene expression in the sheep fetus during late gestation:
Developmental regulation by cortisol. Endocrinology.137:1650-1657.
Louey, S, ML Cock, R Harding. 2005. Long term concsequences of low
birthweight on postnatal growth, adiposity and brain weight at maturity in
sheep. Journal of Reproduction and Development. 51:59-68
Murotsuki, J, JRG Challis, VKM Han, LJ Fraher, R Gagnon. 1997. Chronic fetal
placental embolization and hypoxemia cause hypertension and myocardial
hypertrophy in fetal sheep. American Journal of Physiology. 272:R201R207.

114

Oliver, MH, JE Harding, BH Breier, PD Gluckman. 1996. Foetal insulin-like
growth factor (IGF)-I and IGF-II are regulated differently by glucose or
insulin in the sheep foetus. Reproduction and Fertility. 8:167-172.
Regnault, TRH, B De Vrijer, HL Galan, ML Davidsen, KA Trembler, FC Battaglia,
RB Wilkensing, RV Anthony. 2003. The relationship between
transplacental O2 diffusion and placental expression of PIGF, VEGF and
their receptors in a placental insufficiency model of fetal growth restriction.
Journal of Physiology. 550:641-656.
Reyonlds, LP, PP Borowicz, KA Vonnahme, ML Johnson, AT Gazul-Bilska, DA
Redmer, JS Caton. 2005a. Placental angiogenesis in sheep models of
compromised pregnancy. Journal of Physiology. 565:43-58.
Reyonlds, LP, PP Borowicz, KA Vonnahme, ML Johnson, AT Gazul-Bilska, JM
Wallace, JS Caton, DA Redmer. 2005b. Animal models of placental
angiogenesis. Placenta. 26:689-708.
Samson, F, F Bonnet, M Heimburger, C Rucker-Martin, DO Levitsky, GM
Mazmanian, JJ Mercadier, A Serraf. 2000. Left ventricular alterations in a
model of fetal left ventricular overload. Pediatric Research. 48:43-49.
Sinclair, KD, TG McEvoy, EK Maxfield, CA Maltin, LE Young, I Wilmut, PJ
Broadbent, JJ Robinson. 1999. Aberrant fetal growth and development
after in vitro culture of sheep zygotes. Journal of Reproduction and
Fertility. 116:177-186.
Stelwagen, K, DG Grieve, JS Walton, JL Ball, BW McBride. 1994. Effects of
bovine somatotropin administration during the last trimester of gestation
on maternal growth, and fetal and placental development in primigravid
ewes. Animal Production. 58:87-94.
Suttie, JM, EA Lord, PD Gluckman, PF Fennessy, RP Littlejohn. Genetically lean
and fat sheep differ in their growth hormone response to growth hormonereleasing factor. Domestic animal Endocrinology. 8:323-329.
Thureen, PJ, KA Trembler, G Meschia, EL Makowski, RB Wilkening. 1992.
Placental glucose transport I heat-induced fetal growth retardation.
American Journal of Physiology. 263:R578-R585.
Vonnahme, KA, BW Hess, TR Hansen, RJ McCormick, DC Rule, GE Moss, WJ
Murdoch, MJ Nijland, DC Skinner, PW Nathanielsz, SP Ford. 2003
Maternal undernutrition from early-to mid-gestation leads to growth
retardation, cardiac ventricular hypertrophy, and increased liver weight in
the fetal sheep. Biology of Reproduction. 69:133-140.

115

Wallace, JM, M Matsuzaki, J Milne, R Aitken. 2006. Late but not early gestation
maternal growth hormone treatment increases fetal adiposity in
overnourished adolescent sheep. Biology of Reproduction. 75:231-239.
Wallace, JM, JS Milne, RP Aitken. 2004. Maternal growth hormone treatment
from day 35 to 80 of gestation alters nutrient partitioning of uteroplacental
growth in the overnourished adolescent sheep. Biology of Reproduction.
70:1277-1285.
Wallace, JM, TRH Regnault, SW Limesand, WW Hay Jr, RV Anthony. 2005.
Investigating the cause of low birth weight contrasting ovine paradigms.
Journal of Physiology. 565:19-26.
Wu, G, FW Baze,r TA Cudd, CJ Meininger, TE Spencer. 2004. Maternal nutrition
and foetal development. Journal of Nutrition. 134 2169-2172.
Wu, G, FW Bazer, JM Wallace, TE Spencer. 2006. BOARD-INIVTED REVIEW:
Intrauterine growth retardation: Implications for the animal sciences.
Journal of Animal Science. 84 2316-2337.

116

Literature Cited
Aguilar, J, M Reyley. 2005. The uterine tubal fluid: secretion, composition and
biological effects. Animal Reproduction. 2:91-105.
Anderson, LL, S Jeftinija, CG Scanes. 2004. Growth hormone secretion:
Molecular and cellular mechanisms and in vivo approaches. Experimental
Biology and Medicine. 229:291-302.
Armitage, JA, YK Imran, PD Taylor, PW Nathanielsz, L Poston. 2004.
Developmental programming of the metabolic syndrome by maternal
nutritional imbalance: how strong is the evidence from experimental
models in mammals. Journal of Physiology. 561:355-377.
Ashworth, CJ, FW Bazer. 1989. Changes in ovine conceptus and endometrial
function following asynchronous embryo transfer or administration of
progesterone. Biology of Reproduction. 40:425-433.
Bassett, NA, PD Gluckman. 1986. Pulsatile growth hormone secretion in the
ovine fetus and neonatal lamb. Journal of Endocrinology. 109:307-312.
Bauer, MK, BB Breier, FH Bloomfield, EC Jensen, PD Gluckman, JE Harding.
2003. Chronic pulsatile infusion of growth hormone to growth-restricted
foetal sheep increases circulating foetal insulin-like growth factor-I levels
but not foetal growth. Journal of Endocrinology. 177:83-92.
Bauer, MK, JE Harding, BH Breier, PD Gluckman. 2000. Exogenous GH infusion
to late-gestational foetal sheep does not alter foetal growth and
metabolism. Journal of Endocrinology. 166:591-597.
Bauer, MK, JE Harding, NS Bassett, BH Breier, MH Oliver, BH Gallaher, PC
Evans, SM Woodall, PD Gluckman. 1998. Fetal growth and placental
function. Molecular and Cellular Endocrinology. 140:115-120.
Bazer, FW, RM Roberts, SM Mahalboob Basha, MT Zavy, D Caton, DH Barron.
1979. Method for obtaining ovine uterine secretions from unilaterally
pregnant ewes. Journal of Animal Science. 49:1522-1527.
Bell, AW, BW McBride, R Slepetis, RJ Early, WB Currie. 1989. Chronic heat
stress and prenatal development in sheep: I. Conceptus growth and
maternal plasma hormones and metabolites. Journal of Animal Science.
67:3289-3299.
Bell, AW, WW Hay Jr., RA Ehrhardt. 1999. Placental transport of nutrients and its
implications for fetal growth. Journal of Reproduction and Fertility
Supplement. 54:401-410.

117

Bjorkman, N. 1965. Fine structure of the ovine placentome. Journal of Anatomy.
99:283-297.
Bloomfield, FH, MK Bauer, PL Van Zijl, PD Gluckman, JE Harding. 2002.
Amniotic IGF-I supplements improve gut growth but reduce circulating
IGF-I in growth-restricted fetal sheep. American Journal of Physiology.
282:E259-E269.
Bloomfield, FH, PL van Zijl, MK Bauer, HH Phua, JE Harding. 2006. Effect of
pulsatile growth hormone administration to the growth-restricted foetal
sheep on somatotrophic axis gene expression in foetal and placental
tissues. American Journal of Physiology. 291:E333-E339.
Borowicz, PP, DR Arnold, ML Johnson, AT Grazul-Bilska, DA Redmer, LP
Reynolds. 2007. Placental growth throughout the last two thirds of
pregnancy in sheep: vascular development and angiogenic factor
expression. Biology of Reproduction. 76:259-267.
Brameld, JM, A Mostyn, J Dandrea, TJ Stephenson, JM Dawson, PJ Buttery, ME
Symonds. 2000. Maternal nutrition alters the expression of insulin-like
growth factors in fetal sheep liver and skeletal muscle. Journal of
Endocrinology. 167:429-437.
Breier, BH, GR Ambler, H Sauerwein, A Surus, PD Gluckman. 1994. The
induction of hepatic somatotrophic receptors after birth in sheep is
dependent on parturition-associated mechanisms. Journal of
Endocrinology. 141:101-108.
Bubb, KJ, ML Cock, MJ Black, M Dodic, WM Boon, HC Parkington, R Harding, M
Tare. 2007. Intrauterine growth restriction delays cardiomyocyte
maturation and alters coronary artery function in the foetal sheep. Journal
of Physiology. 578:871-881.
Buhi, WC, IM Alvarex, AJ Kouba. 2000. Secreted proteins of the ovidcut. Cells
Tissues Organs. 166:165-179.
Burrell, JH, AM Boyn, V Kumarsamy, A Hsieh, SI Head, ER Lumbers. 2003.
Growth and maturation of cardiac myocytes in foetal sheep in the second
half of gestation. Anatomical Research. 274A:952-961.
Cetin, I. 2001. Amino acid interconversions in the fetal-placental unit: The animal
model and human studies in vivo. Pediatric Research 49:148-154.
Corstius, HB, MA Zimanyi, N Maka, T Herath, W Thomas, A Van Der, Laarse,
NG Wreford, MJ Black. 2005. Effect of intrauterine growth restriction on
the number of cardiomyocytes in rat hearts. Pediatric Research. 57:796800.

118

Costine, BA, EK Inskeep, ME Wilson. 2005. Growth hormone at breeding
modifies concetpus development and postnatal growth in sheep. Journal
of Animal Science. 83:810-815.
Crisman, RO, LE McDonald, FN Thompson. 1980. Effects of progesterone or
estradiol on uterine tubal transport of ova in the cow. Theriogenology.
13:141-147.
Currie, MJ, NS Bassett, PD Gluckman. 1997. Ovine glucose transporter-1 and-3:
cDNA partical sequences and developmental gene expression in the
placenta. Placenta. 18:393-401.
Dandrea, JV Wilson, G Gapalakrishnan, L Heasman, H Budge, T Stephenson,
ME Symonds. 2001. Maternal nutritional manipulation of placental growth
and glucose transpoter 1 (GLUT-1) abundance in sheep. Reproduction.
122:793-800.
Das, UG, J He, RA Ehrhardt, WW Hay Jr., SU Devaskar. 2000. Time-dependent
physiological regulation of ovine placental GLUT-3 glucose transporter
protein. American Journal of Physiology. 279:R2252-R2261.
De Zegher, F, J Daaboul, MM Grumbach, SL Kaplan. 1989. Hormone ontogeny
in the ovine fetus and neonate. XXII. The effect of somatostatin on the
growth hormone (GH) response to GH-Releasing Factor. Endocrinology.
124:1114-1117.
Douglas, RG, PD Gluckman, K Ball, B Breier, JHF Shaw. 1991. The effects of
infusion of insulin like growth factor (IGF) I, IGF-II, and insulin on glucose
and protein metabolism in fasted lambs. Journal of Clinical investigation.
88:614-622.
Ehrhardt, RA, AW Bell. 1995. Growth and metabolism of the ovine placenta
during mid-gestation. Placenta. 16:727-741.
Ehrhardt, RA, AW Bell. 1997. Developmental increases in glucose transporter
concentration in sheep placenta. American Journal of Physiology.
273:R1132-R1141.
Ford, SP, BW Hess, MM Schwope, MJ Nijland, JS Gilbert, KA Vonnahme, WJ
Means, H Han, PW Nathanielsz. 2007. Maternal undernutrition during
early to mid-gestation in the ewe results in altered growth, adiposity, and
glucose tolerance in male offspring. Journal of Animal Science. 85:12851294.
Fowden, A.1995. Endocrine regulation of foetal growth. Reproduction Fertility
and Development. 7:351-363.

119

Fowden, AL, JW Ward, FPB Wooding, AJ Forhead, M Constancia. 2006.
Programming placental nutrient transport capacity. Journal of Physiology.
572:5-15.
Galan, HL, MJ Hussey, A Barbera, E Ferrazzi, M Chung, JC Hobbins, FC
Battaglia. 1999. Relationship of fetal growth to duration of heat stress in
an ovine model of placental insufficiency. American Journal of Obstetrics
and Gynecology. 180:1278-1282.
Gandolfi, F, RM Moor. 1987. Stimulation of early embryonic development in the
by co-culture with oviduct epithelial cells. Journal of Reproduction and
Fertility. 81:23-28.
Gandolfi, F, AL Tiziana, AL Brevini, L Richardson, CR Brown, MR Moor.
1989Characterization of proteins secreted by sheep oviduct epithelial cells
and their function in embryonic development. Development. 106:303-312.
Gatfor, KL, TP Fletcher, A Rao, AR Egan, BJ Hosking, IJ Clark. 1997. GH, GHreleasing factor and somatostain in growing lambs: sex differences and
mechanisms for sex differences. Journal of Endocrinology. 152:19-27.
Gluckman, PD, BH Breier, SR Davis. 1986.Phyiology of the somatotrophic axis
with particular reference to the ruminant. Journal of Dairy Science. 70:442466.
Gluckman PD, GS Pinal. 2003 Regulation of foetal growth by the somatotrophic
axis. Journal of Nutrition. 133 1741S-1746S.
Gluckman, PD, JH Buttler. 1983. Parturition-related changes in insulin-like
growth factors-I and –II in the perinatal lamb. Journal of Endocrinology.
99:223-232.
Gluckman, PD, PL Mueller, SL Kaplan, AM Rudolph, MM Grumbach. 1979a.
Hormone ontogeny in the ovine fetus. I. Circulating growth hormone in mid
and late gestation. Endocrinology. 104:162-168.
Gluckman, PD, PL Mueller, SL Kaplan, AM Rudolph, MM Grumbach. 1979b.
Hormone ontogeny in the ovine fetus. III. The effect of exogenous
somatostatin. Endocrinology. 104:974-978.
Godfery, KM, DJP Barker. 2000. Foetal nutrition and adult disease. American
Journal of Clinical Nutrition. 71:1344S-1352S.
Gootwine, E, TE Spencer, FW Bazer. 2007Litter-size-dependent intrauterine
growth restriction in sheep. Animal. 1:547-564.

120

Gray, CA, FF Bartol, KM Taylor, AA Wiley, WS Ramsey, TL Ott, FW Bazer, TE
Spencer. 2000. Ovine uterine gland knock-out model: effects of gland
ablation on the estrous cycle. Biology for Reproduction. 62:448-456.
Gray, CA, KM Taylor, WS Ramsey, JR Hill, FW Bazer, FF Bartol, TE Spencer.
2001. Endometrial glands are required for preimplantation conceptus
elongation, and survival. Biology of Reproduction. 64.1608-1613.
Gray, CA, RC Burghardt, GA Johnson, FW Bazer, TE Spencer. 2002. Evidence
that absence of endometrial gland secretions in uterine gland knockout
ewes compromises conceptus survival and elongation. Reproduction.
124:289-300.
Harding, JE, PC Evans, PD Gluckman. 1997. Maternal growth hormone
treatment increases placental diffusion capacity but not foetal or placental
growth in sheep. Endocrinology. 138 5352-5358.
Harding, JE, L Liu, PC Evans, PD Gluckman. 1994. Insulin-like growth factor 1
alters feto-placental protein and carbohydrate metabolism in fetal sheep.
Endocrinology. 134:1509-1514/
Hay, WW. 1995. Regulation of placental metabolism by glucose supply.
Reproduction Fertility and Development. 7:365-375.
Heasman, L, L Clarke, K Firth, T Stephenson, ME Symonds. 1998. Influence of
restricted maternal nutrition in early to mid gestation on placental and fetal
development at term in sheep. Pediatric Rsearch. 44:546-551.
Holaskova, I. 2007. I. Distribution of Transforming Growth Factor Beta 1, TGF
receptor II and Decorin in the Sheep Uterus Shortly After Breeding II.
Effect of TGF Beta 1 on Gene Expression in the Sheep Uterus at the Time
of Embryo Attachment III. Concentration of TGF Beta 1, 2, and 3 in Beef
Bull and Ram Seminal Plasma, Dissertation, West Virginia University.
Igwebuike, UM. 2006. Trophoblast cells of ruminant placentas-A minireview.
Animal Reproduction Science. 93:185-198.
Jansson, N, J Pettersson, A Haafiz, A Ericsson, I Palmberg, M Tranberg, V
Ganapahty, TL Powell, T Jansson. 2006. Down-regulation of placental
transport of amino acids precedes the development of intrauterine growth
restriction in rates fed low protein diet. Journal of Physiology. 576:935946.
Jansson, T. 2001. Amino acid transporters in the human placenta. Pediatric
Research. 49:141-147
Jansson, T, M Wennergren, NP Illsley. 1993. Glucose transportere protein
expression in human placenta throughout gestation and in intrauterine
121

growth retardation. Journal of Clinical Endocrinology and Metabolism.
77:1554-1562.
Jensen, EC, JE Harding, MK Bauer, PD Gluckman. 1999. Metabolic effects of
IGF-I in the growth retarded fetal sheep. Journal of Endocrinology.
161:485-494.
Jozwik, M, C Teng, RB Wilkening, G Meschia, FC Battaglia. 2004. Reciprocal
inhibition of umbilical uptake within groups of amino acids. American
Journal of Physiology. 286:E376-E383.
Killian, GJ. 2004. Evidence for the role of oviduct secretions in sperm function,
fertilization and embryo development. Aminal Reproduction Science. 8283:141-153.
Kleemann, DO, SK Walker, RF Seamark. Enhanced fetal growth in sheep
administered progesterone during the first three days of pregnancy.
Journal of Reproduction and Fertility. 102:411-417.
Koch, JM, JS Moritz, DC Lay Jr, ME Wilson. 2007. Effect of melengestrol acetate
as an alternative to induce molting in hens on the expression of yolk
proteins and turnover of oviductal epithelium. Animal Reproduction
Science. 102:14-23.
Kwon, H, SP Ford, FW Bazer, TE Spencer, PW Nathanielsz, MJ Nijland, BW
Hess, G Wu. Maternal nutrient restriction reduces concentrations of amino
acids and polyamines in ovine maternal and fetal plasma and fetal fluids.
Biology of Reproduction. 71:901-908.
Kudo, Y, CA Boyd. 2002. Human placental amino acid transporter genes:
Expression and function. Reproduction. 124:593-600.
Lang, U, RS Baker, J Khoury, KE Clark. 2000. Effects of chronic reduction in
uterine blood flow on fetal and placental growth in the sheep. American
Journal of Physiology. 279:R53-R59.
Lemley, CO, Koch JM, Blemings KP, Krause KM, and Wilson ME. 2008a.
Concomitant changes in progesterone catabolic enzymes, cytochrome
P450 2C and 3A, with plasma insulin concentrations in ewes
supplemented with sodium acetate or sodium propionate. Animal. (In
Press).
Lemley CO, Butler ST, Butler WR, and Wilson ME. 2008b. Short communication:
insulin alters hepatic progesterone catabolic enzymes, cytochrome P450
2C and 3A, in dairy cows. Journal of Dairy Science. 91:641-645.

122

Lemons, JA, EW Adcock III, D Jones Jr. MA Naughton, G Meschia, FC Battaglia.
1976. Umbilical uptake of amino acids in the unstressed fetal lamb. The
Journal of Clinical Investigation. 58:1428-1434.
Li, J, JA Owens, PC Owens, JC Saunders, AL Fowden, RS Gilmour. 1996. The
ontogeny of hepatic growth hormone receptor and insulin-like growth
factor I gene expression in the sheep foetus during late gestation:
Developmental regulation by cortisol. Endocrinology: 137:1650-1657.
Limesand, SW, TRH Regnault, WW Hay Jr. 2004. Characterization of glucose
transporter 8 (GLUT*) in the ovine placenta of normal and growth
restricted fetuses. Placenta. 25:70-77.
Lok, F, JA Owends, L Mundy, JS Robinson, PC Owens. 1996. Insulin-like growth
factor I promotes growth selectively in fetal sheep in late gestation.
American Journal of Physiology. 270:R1148-1155.
Louey, S, ML Cock, R Harding. 2005. Long term concsequences of low
birthweight on postnatal growth, adiposity and brain weight at maturity in
sheep. Journal of Reproduction and Development. 51:59-68
Luther, J, J Miline, R Aitken, M Matsuzaki, L Reynolds, D Redmer, J Wallace.
2007. Placental growth, angiogenci gene expression, and vascular
development in undernourished adolescent sheep. Biology of
Reproduction. 77:351-357.
Maxfield, EK, KD Sinclair, LD Dunne, PJ Broadbent, µ Robison, E Steward, DG
Kyle, CA Maltin. 1998. Temporary exposure of ovine embryos to an
advanced uterine environment does not affect fetal weight but alters fetal
muscle development. Biology of Reproduction. 59:321-325.
McGivan, JD, M Pastor-Anglada. 1994. Regulatory and molecular aspects of
mammalian amino acid transport. Biochemistry Journal. 299:321-334.
Molina, RD, G Meschia, FC Battaglia, WW Hay. 1991. Gestational maturation of
placental glucose transfer capacity in sheep. American Journal of
Physiology. 261:R697-R704.
Moore, NW, JN Shelton. 1964. Egg transfer in sheep: Effect of degree of
synchronization between donor and recipient, age of egg, and site of
transfer on the survival of transferred eggs. Journal of Reproduction and
Fertility. 7:145-152.
Murotsuki, J JRG Challis, VKM Han, LJ Fraher, R Gagnon. 1997. Chronic foetal
placental embolization and hypoxemia cause hypertension and myocardial
hypertrophy in fetal sheep. American Journal of Physiology. 272:R201R207.

123

Murray, M. 1991. Microsomal cytochrome P450-dependent steroid metabolism in
male sheep liver. Quantitative importance of 6ß-hydroxylation and
evidence for the involvement of a P450 from the IIIA subfamily in the
pathway. Journal of Steroid Biochemistry and Molecular Biology. 38:611619.
Murray, M. 1992. Participation of a cytochrome P450 enzyme from the 2C
subfamily in progesterone 21-hydroxylation in sheep liver. Journal of
Steroid Biochemistry and Molecular Biology. 43:591-593.
Murray, MK. 1993. An estrogen-dependent glycoprotein is synthesized and
released from the oviduct in a temporal- and region-specific manner
during early pregnancy in the ewe. Biology of Reproduction. 48:446-453.
Murotsuki, J, JRG Challis, VKM. Han, LJ Fraher, R Gagnon. 1997. Chronic fetal
placental embolization and hypoxemia cause hypertension and myocardial
hypertrophy in fetal sheep. American Journal of Physiology. 272:R201R207.
Nancarrow, CD, JL Hill. 1995. Oviduct proteins in fertilization and early embryo
development. Journals of Reproduction and Fertility. Suppl. 49:3-13.
Nathanielsz, PW. 2000. Fetal programming: How the quality of fetal life alters
biology for a lifetime. NeoReviews. 1:126-131
Noyan-Ashraf, MH, L Wu, R Wang, BHJ Jurlink. 2006. Dietary approaches to
positively influence fetal determinants of adult health. FASEB Journal.
20:371-373.
Oliver, MH, JE Harding, BH Breier, PD Gluckman. 1996. Fetal insulin-like growth
factor (IGF)-I and IGF-II are regulated differently by glucose or insulin in
the sheep foetus. Reproduction Fertility and Development. 8:167-172.
Osgerby, JC, DC Wathers, DH Howard, TS Gass. 2002. The effect of maternal
undernutrition on ovine fetal growth. Journal of Endocrinology. 173:131141.
Osgerby, JC, DC Wathers, DH Howard, TS Gass. 2004. The effect of maternal
undernutrition on the placental growth trajectory and the uterine insulinlike growth factor axis in the pregnant ewe. Journal of Endocrinology.
182:89-103.
Ott, TL, AA Wiley, FF Bartol. 1997. Effects of stage of gestation and uterine
ligation on ovine placentome development and glycosaminoglycans.
Journal of Animal Science. 75:1053-1062.
Polkowska, J. 1995. Development of the gonadotrophic and somatotrophic axes
of sheep. Journal of Reproduction and Fertility Supplement. 49:187-195.
124

Ravelli, AC, JH. Meulen, C Osmond, DP. Barker, OP. Bleker. 1999. Obesity at
the age of 50 y in men and women exposed to famine prenatally.
American Journal of Clinical Nutrition. 70:811-816
Ravelli, GP, ZA Stein, MW Susser. 1976. Obesity in young men after famine
exposure in utero and early infancy. The New England Journal of
Medicine. 295:349-353
Redmer, DA, RP Aitken, JS Milne, LP Reynolds, JM Wallace. 2005. INfulence of
maternal nutrition on messenger RNA expression of placental angiogenic
factors and their receptors at midgestation in adolescent sheep. Biology of
Reproduction. 72:1004-1009.
Regnault, TRH, B De Vrijer, HL Galan, ML Davidsen, KA Trembler, FC Battaglia,
RB Wilkensing, RV Anthony. 2003. The relationship between
transplacental O2 diffusion and placental expression of PIGF, VEGF and
their receptors in a placental insufficiency model of fetal growth restriction.
Journal of Physiology. 550:641-656.
Regnault, TRH, JE Friedman, RB Wilkening, RV Anthony, WW Hay Jr. 2005.
Fetoplacental transport and utilization of amino acids in IUGR-a review.
Placenta. 26:S52-S62.
Reynolds, LP, DA Redmer. 1995. Utero-lacental vascular development and
placental function. Journal of Animal Science. 73:1839-1851.
Reyonlds, LP, PP Borowicz, KA Vonnahme, ML Johnson, AT Gazul-Bilska, DA
Redmer, JS Caton. 2005a. Placental angiogenesis in sheep models of
compromised pregnancy. Journal of Physiology. 565:43-58.
Reyonlds, LP, PP Borowicz, KA Vonnahme, ML Johnson, AT Gazul-Bilska, JM
Wallace, JS Caton, DA Redmer. 2005b. Animal models of placental
angiogenesis. Placenta. 26:689-708.
Rivera, RM, CR Youngs, SP Ford. 1996. A comparison of the number of inner
cell mass and trophectoderm cells of preimplantation meishan and
Yorkshire pig embryos at similar developmental states. Journal of
Reproduction and Fertility. 106:111-116.
Roberston, AF, WB. Karp. 1976. Placental transport of nutrients. Southern
Medical Journal. 69:1358-1362.
Robinson, J, S Chidzanja, K Kind, F Lok, P Owens, J Owens. 1995. Placental
control of fetal growth. Journal of Reproduction Fertility and Development.
7:333-344.

125

Rosenfeld, CR, FH Morriss Jr., EI Makowski, G Meschia, FC Battaglia. 1974.
Circulatory changes in the reproductive tissues of ewes during pregnancy.
Gynecological Investigation. 5: 252-568.
Rowson, LEA, RM Moor. 1966. Embryo transfer in the sheep: The significance of
synchronizing oestrus in the donor and recipient animal. Journal of
Reproduction and Fertility. 11:207-212.
Samson, F, F Bonnet, M Heimburger, C Rucker-Martin, DO Levitsky, GM
Mazmanian, JJ Mercadier, A Serraf, 2000. Left ventricular alterations in a
model of fetal left ventricular overload. Pediatric Research. 48:43-49.
Senger, PL. 1999. Pathways to Pregnancy and Parturition. 2nd Edition. Current
Conceptions, Inc.
Sheffel, CE, BR Pratt, WL Ferrell, EK Inskeep. 1982. Induced corpora lutea in the
postpartum beef cow. II. Effects of treatment with progestogen and
gonadotropins. Journal of Animal Science. 54:830-836.
Sinclair, KD, TG McEvoy, EK Maxfield, CA Maltin, LE Young, I Wilmut, PJ
Broadbent, JJ Robinson. 1999. Aberrant fetal growth and development
after in vitro culture of sheep zygotes. Journal of Reproduction and Fetility.
116:177-186.
Smith, DL, BM Stinefelt, KP Blemings, ME Wilson. 2006. Diet-induced alterations
in progesterone clearance appear to be mediated by insulin signaling in
hepatocytes. Journal of Animal Science. 84:1102-1109.
Spencer, TE, FW Bazer. 2004. Uterine and placental factors regulating
conceptus growth in domestic animals. Journal of Animal Science Suppl.
82:E4-E13.
Spencer, TE, GA Johnson, FW Bazer, RC Burghardt. 2004. Implantation
mechanisms: insights from the sheep. Reproduction. 128:657-668.
Stelwagen, K, DG Grieve, JS Walton, JL Ball, BW McBride. 1994. Effects of
bovine somatotropin administration during the last trimester of gestation
on maternal growth, and foetal and placental development in primigravid
ewes. Animal Production. 58:87-94.
Stokes, H, JM Boda. 1968. Immunofluorescent localization of growth hormone
and prolactin in the adenohypophysis of fetal sheep. Endocrinology.
83:1362-1366.
Suttie, JM, EA Lord, PD Gluckman, PF Fennessy, RP Littlejohn. Genetically lean
and fat sheep differ in their growth hormone response to growth hormonereleasing factor. Domestic animal Endocrinology. 8:323-329.

126

Sutton, R, CD Nancarrow, ALC Wallace. 1986. Oestrogen and seasonal effects
on the production of an oestrus-associated glycoprotein in oviducal fluid of
sheep. Journal of Reproduction and Fertility. 77:645-653.
Thomas, VM, RW Kott. A review of Montana winter range ewe nutrition research.
1995. 11:17-24.
Thureen, PJ, KA Trembler, G Meschia, EL Makowski, RB Wilkening. 1992.
Placental glucose transport I heat-induced fetal growth retardation.
American Journal of Physiology. 263:R578-R585.
Vonnahme KA, BW Hess, MJ Nijland, PW Nathanielsz, SP Ford. 2006.
Placentomeal differentiation may compensate for maternal nutrient
restriction in ewes adapted to harsh range conditions. Journal of Animal
Science. 84:3451-3459.
Vonnahme KA, BW Hess, TR Hansen, RJ McCormick, DC Rule, GE Moss, WJ
Murdoch, MJ Nijland, DC Skinner, PW Nathanielsz, SP Ford. 2003
Maternal undernutrition from early-to mid-gestation leads to growth
retardation, cardiac ventricular hypertrophy, and increased liver weight in
the foetal sheep. Biology of Reproduction. 69:133-140.
de Vrijer, B, TRH Regnault, RB Randall, B Wilkening, G Meschia, FG Battaglia.
2004. Pladntal uptake and transport of ACP, a neutral nonmetabolizable
amino acid, in an ovine model of fetal growth restriction. American Journal
of Physiology. 287:E1114-E1124.
Wallace, J, D Bourke, P Da Silva, R Aitken. 2001. Nutrient partitioning during
adolescent pregnancy. Reproduction. 122:347-357.
Wallace, JM, DA Bourke, RP Aitken, JS Milne, WW Hay Jr. 2002a. Placental
glucose transport in growth-restricted pregnancies induced by
overnourishing adolescent sheep. Journal of Physiology. 547:85-94.
Wallace, JM, DA Bourke, RP Aitken, N Leitch, WW Hay Jr. 2002b. Blood flows
and nutrient uptakes in growth=restricted pregnancies induced by
overnourishing adolescent sheep. American Journal of Physiology. 282:
R1027-R1036.
Wallace, JM, M Matsuzaki, J Milne, R Aitken. 2006. Late but not early gestation
maternal growth hormone treatment increases fetal adiposity in
overnourished adolescent sheep. Biology of Reproduction. 75 231-239.
Wallace, JM, JS Milne, DA Redmer, RP Aitken. 2006b. Effect of diet composition
on pregnancy outcome in overnourished rapidly growing adolescent
sheep. British Journal of Nutrition. 96:1060-1068.

127

Wallace, JM, JS Milne, RP Aitken. 2004. Maternal growth hormone treatment
from day 35 to 80 of gestation alters nutrient partitioning of uteroplacental
growth in the overnourished adolescent sheep. Biology of Reproduction.
70:1277-1285.
Wallace, JM, RP Aitken, JS Milne, WW Hay Jr. 2004. Nutritionally mediated
placental growth restriction in the growing adolescent: Consequences for
the fetus. Biology of Reproduction. 71:1055-1062.
Wallace, JM, TRH Regnault, SW Limesand, WW Hay Jr, RV Anthony. 2005.
Investigating the cause of low birth weight contrasting ovine paradigms.
Journal of Physiology. 565 19-26.
Watson, AJ, PH Watson, M Arcellanal-Panlilio, D Warnes, SK Walker, GA
Schultz, DT Armstrong, RF Seamark. 1994. A Growth phenotype map for
ovine preimplantation and development. Biology of Reproduction. 50:725733.
Wilmut, I, DI Sales. 1981. Effect of an asynchronous environment on embryonic
development in sheep. Journal of Reproduction and Fertility. 61:179-184.
Wooding, FBP, AL Fowden, AW Bell, RA Ehrhardt, SW Limesand, WW Hay.
2005. Localisation of glucose transport in the ruminant placenta:
Implications for sequential use of transporter isoforms. Placenta. 26:626640.
Wu, G, FW Baze,r TA Cudd, CJ Meininger, TE Spencer. 2004. Maternal nutrition
and foetal development. Journal of Nutrition. 134 2169-2172.
Wu, G, FW Bazer, JM Wallace, TE Spencer. 2006. BOARD-INIVTED REVIEW:
Intrauterine growth retardation: Implications for the animal sciences.
Journal of Animal Science. 84 2316-2337.
Young, LE, SC Butterwith, I Wilmut. 1996. Increased ovine foetal weight following
transient asynchronous embryo transfer is not associated with increased
placental weight at day 21 of gestation. Theriogenology. 45:231.

Digitally signed by John H. Hagen
DN: cn=John H. Hagen, o=West
Virginia University Libraries,
ou=Acquisitions Department,
email=John.Hagen@mail.wvu.edu,
c=US
Reason: I am approving this document
Date: 2008.05.08 18:22:49 -04'00'

128

